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Abstract
Numerous deaths, tragedies, and underreported drug side effects occur in outsourced
clinical trials. Total quality system breakdowns occur even though quality agreement
contracts and quality management systems are used by pharmaceutical organizations. The
purpose of this single case study was to explore strategies clinical quality assurance
managers use to avoid breakdowns in quality with outsourced clinical trials in AsiaPacific countries. The study included a purposeful sample of 15 clinical quality assurance
managers from 1 pharmaceutical organization located in the Northeast region of the
United States. The conceptual framework was von Bertalanffy’s general systems theory.
Face-to-face semistructured interviews or e-mail questionnaires containing open-ended
questions were used to gather data from clinical quality assurance managers who had a
minimum of 5 years of experience with outsourced clinical trials. Coded data and themes
were identified through the modified van Kaam method. The three emergent themes were
the following: vendor quality management, building quality in outsourced clinical trials,
and quality management systems. Results of the study may contribute to social change by
helping pharmaceutical organizations’ leaders develop strategies and tools to improve the
quality of outsourced clinical trials.
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Section 1: Foundation of the Study
Background of the Problem
Global pharmaceutical companies have been confronted with various challenges
that affect their long-term viability. Challenges such as increased drug prices (Pronker,
Geerts, Cohen, & Pieterse, 2011) and tighter regulatory drug approval policies to ensure
data integrity and to prevent fraud must be addressed by pharmaceutical managers.
Additional challenges are new clinical regulatory requirements making it difficult for
pharmaceutical research and development (R&D) operations to perform clinical trials and
approve a new drug (Pronker et al., 2011). The high cost of conducting clinical trials
forces the pharmaceutical leaders to outsource clinical trials to developing countries.
Pharmaceutical organizations address these challenges by creating an outsourcing clinical
trial model for R&D sectors in Asia-Pacific developing countries. The outsourced clinical
trial model saves money and time, and provides faster drug approval (Mendivil, 2012).
Globalization of clinical trials increases complexity and makes it difficult to achieve
global quality and patient safety (Paul, Mytelka, & Dunwiddie, 2011). According to Bate,
Mooney, and Hess (2011), 1,589 out of 1,940 drugs were identified as registered in
developing countries; 351 drugs were not registered, and there was limited information
on their clinical trials and known side effects. Because of the complexity of clinical trials
and faster completion timelines, drugs’ side effects are underreported, and unregistered
drugs are causing thousands of deaths and hospitalizations. In addition, there are over
3,000 deaths and 300,000 tragedies occurring in outsourced clinical trials conducted in
developing countries (Soni & Singh, 2013).
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Problem Statement
The high cost of conducting clinical trials is forcing pharmaceutical leaders in the
United States to outsource clinical trials to Asia-Pacific countries (Mendivil, 2012).
Outsourced clinical trials, which represent 60% of clinical trials worldwide, are causing a
disproportionate number of deaths, tragedies, and underreported drug side effects (Soni &
Singh, 2013). The general business problem is a disproportionate number of deaths,
tragedies, and underreported drugs’ side effects continue to occur despite contracted
quality standards and the inclusion of quality management systems. The specific business
problem is some clinical quality assurance managers lack strategies to avoid a breakdown
in quality with outsourced clinical trials in Asia-Pacific countries.
Purpose Statement
The purpose of this qualitative case study was to explore strategies clinical quality
assurance managers use to avoid a breakdown in quality with outsourced clinical trials in
Asia-Pacific countries. The targeted population consisted of clinical quality assurance
managers from one pharmaceutical organization located in the Northeast region of the
United States. The information provided by the clinical quality assurance managers may
contribute to social change through the identification of strategies to avoid quality
breakdowns with outsourced clinical trials.
Nature of the Study
The qualitative research method was used to explore the research participants’
experiences (Corbin & Strauss, 2014). Qualitative research was the appropriate method
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because it is used to provide an in-depth description of the phenomenon from direct
fieldwork observations, documents, and open-ended interviews (Patton, 2005).
Qualitative research methods offered flexibility, which helped me gain a better
understanding of the quality management system breakdowns that occur during the
outsourcing of clinical trials (Denzin & Lincoln, 2011; Corbin & Strauss, 2014). A
quantitative approach was not appropriate because the purpose of the study was not to
test a hypothesis, make predictions, or evaluate cause and effect of outsourced clinical
trials (Bernard, 2013). A mixed-methods approach was also inappropriate because the
research question did not require both qualitative and quantitative data (Brannen & Moss,
2012; Onwuegbuzie, Frels, Collins, & Leech, 2013).
The design for the doctoral study was a case study. Yin (2014) noted that if the
aim of research is to provide a rich description of a phenomenon, a descriptive case study
is needed. The narrative study design is used to explore the life of an individual and to
report the individual’s experiences. My research study’s aim was not to explore an
individual’s experiences regarding outsourced clinical trials. Grounded theory was also
inappropriate because the focus of the study was not on developing a theory grounded in
the data from the field or studying a process or action involving many individuals. An
ethnographic design is used to describe and interpret a culture-sharing group (Wolcott,
2008). My research study did not focus on describing or interpreting the pharmaceutical
culture. Finally, I excluded a phenomenological design because I did not intend to
explore lived experiences in this study (Barss, 2012).
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Research Question
The central research question proposed for the study was the following: What
strategies do clinical quality assurance managers use to avoid quality breakdowns with
the outsourced clinical trials in Asia-Pacific countries?
Interview Questions
To answer the overarching research question, the following open-ended
semistructured interview questions were used:
1. How do clinical quality assurance managers regulate the clinical quality
management systems and adapt to changes when trials are outsourced to
Asia Pacific?
2. How do clinical quality assurance managers ensure that clinical trial
vendors adapt to the changes in the environment and process negative
feedback?
3. What actions are taken by clinical quality assurance managers to ensure
outsourced clinical trial vendors are following the agreed contracts?
4. What strategies do clinical quality assurance managers employ to ensure
compliance from an outsourced clinical trial vendor after an agreed quality
contract?
5. What are some risks and benefits associated with clinical trials when
outsourced to Asia Pacific?
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6. How do clinical quality assurance managers build successful relationships
with clinical trial vendors and sustain those relationships with an everchanging outsourcing business model?
7. How do clinical quality assurance managers ensure standard methods of
communication of newly released standard operating processes,
regulations, systems, and tools to outsourced clinical trial vendors?
8. In a 1-year time frame, how often do clinical quality assurance managers
and outsourcing vendors reassess quality agreements, contracts, processes,
and potential gaps?
9. What strategies have/have not worked with outsourcing clinical trials to
ensure the highest quality of the clinical trial?
10. Is there any additional information you would like add that I may not have
addressed by the interview questions?
Conceptual Framework
The conceptual framework for the qualitative case study was based on general
systems theory (Stacey, 2011). The general systems theory is a methodology used to
employ a system approach to understanding complex problems and phenomena. The
focus of the general systems theory is on the system structure instead of the system
function. The core concepts of the general systems theory are (a) the whole system is
more than the sum of the parts; (b) the system can be open, closed, or semipermeable to
the environment; (c) feedback is the mediator between system behavior and goal; (d) the
central variable is time; (e) change is seen as a transformation of the system; and (f)
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defining the system environment boundaries will identify and establish what is inside the
system and what is outside in the environment and its subparts from the system as a
whole (Laszlo & Krippner, 1998).
The clinical quality assurance pharmaceutical leaders are seeking an
understanding of how to deal with information and use it for sustainable innovation
(Senge, Smith, & Kruschwitz, 2011). The quality of clinical trials determines the
sustainability and longevity of a pharmaceutical organization. Outsourcing clinical trials
to developing countries such as Asia-Pacific countries adds complexity and increases
quality risks. To address these quality risks, clinical quality assurance managers need to
employ strategies to avoid quality breakdowns with outsourced clinical trials. The general
systems theory served as a conceptual framework for understanding the relationships in
the outsourced clinical trial system (Stacey, 2011). The general systems theory is used to
understand who the individuals are, what is changing, and what the individuals are faced
with (Stacey, 2011). Essentially the purpose of system thinking is to identify
interrelationships rather than things. Advantages of the system thinking approach include
helping one manage and grasp complex situations and uncertainty where there is no
simple situation (Cezarino, Junior, & Correa, 2012).
Operational Definitions
Effectiveness: The extent to which improvement efforts resulted in actual
quantifiable improvements (Golušin, Ivanović, Domazet, & Dodić, 2011).
Offshoring: Another form of outsourcing, specifically outsourcing that happens
aboard (Nieto & Rodríguez, 2011).
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Outsourcing: The process of contracting out noncore activities or transferring
activities to a third party (Crisan, Butilca, Salanta, & Ilies, 2011).
Pharmacovigilance: A scientific activity related to the prevention, assessment,
understanding, and detection of any drug-related issue or problem (Arici, Gelal, Demiral,
& Tuncok, 2015).
Standard operating procedure: The crucial part of a quality system. The global
corporate standard operating procedures provides a standard framework of quality
standards for clinical development. Standard operating procedures are needed to take into
account national regulations and to describe the process at the pharmaceutical
organization to implement at the operational level (Chaikin et al., 2000).
System: A set of two or more interrelated elements with the following properties:
Each element has an effect on the functioning of the whole and is affected by one of the
other elements within the system. In addition, all possible subgroups of the elements have
both properties mentioned above (Ackoff, 1981, pp. 15-16.)
Total quality management: A management method used to enhance the quality of
a business organization (Mazumder, Bhattacharya, & Yadav, 2011).
Vendor risk: An uncertainty of choosing an appropriate vendor which ultimately
affects the performance of a project (Mathew & Das Aundhe, 2011).
Assumptions, Limitations, and Delimitations
Assumptions
Assumptions of a study are unverified claims that the researcher assumed to be
true (Bernard, 2013). One assumption I made for this qualitative research study was that a
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top-ranked pharmaceutical organization’s clinical quality assurance managers could
provide an in-depth description of the quality management system’s utility in monitoring
breakdowns of outsourced clinical trials. The second assumption was the data from
pharmaceutical organization’s audit and inspections reports, outsourced clinical contracts,
federal agencies reports, and clinical trial processes could be used to determine the gaps
within the total quality management system. The third assumption was the 15 clinical
quality assurance managers provided unbiased and truthful answers during their
interviews. A final assumption was the outsourcing companies such as Business Process
Organization (BPO) and Contract Research Organization (CRO) located in Asia Pacific
were outsourcing clinical trials and had potential breaks within their quality management
systems.
Limitations
Limitations in a research study are weaknesses within the study (Bernard, 2013).
The potential weakness of the research study was exploring only one multinational
pharmaceutical organization and not exploring medium and small pharmaceutical
organizations. The second limitation of this qualitative study was the location of the
outsourcing clinical trials organizations. The specific outsourced clinical trials region
targeted for this qualitative study was Asia-Pacific countries. The outsourced clinical trial
regions did not include Europe, South America, Central America, North America, and
Africa. The third limitation was the study participants were from one pharmaceutical
organization located in the Northeast United States. The fourth limitation was the
exclusion of outsourced contract research organization’s participants. The final limitation
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was the inclusion of clinical quality assurance participants and exclusion of all other
quality assurance and clinical trial participants.
Delimitations
The researcher’s selection of the scope or boundaries of the study define the
delimitations (Bernard, 2013). The scope of the study was to explore the quality
management system from one pharmaceutical organization, which was responsible for
performing a particular research development function of the clinical trials. The study did
not include any clinical quality assurance participants outside the Northeast United
States. Clinical quality assurance managers with less than 5 years of experience were not
in the study. The purpose of this qualitative study was to explore the strategies clinical
quality assurance managers needed to avoid a breakdown in quality with outsourced
clinical trials in Asia-Pacific countries. Therefore, the scope of the study included only
clinical quality assurance managers, and all other clinical line functions were excluded.
To understand why breakdowns occurred in outsourced clinical trials, only clinical trial
processes, clinical regulations, and clinical quality management systems were in scope.
All other nonclinical processes and systems were out of scope.
Significance of the Study
Contribution to Business Practice
The research study showed the benefits, risks, and quality issues associated with
outsourcing clinical trials to Asia-Pacific countries. The data collected from this research
study may help pharmaceutical organizational leaders contribute to the effective practice
of business by assessing their outsourcing business model and quality management
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systems. In addition, the data can also enhance quality agreements between
pharmaceutical organizations and outsourcing clinical trial companies to reduce audit
inspection findings and increase approval time on new drugs.
Implications for Social Change
The information provided by clinical quality assurance managers contributed to
social change through the creation of strategies to improve quality with outsourced
clinical trials. The results may also be used to develop outsourced clinical trial best
practices and standard operating procedures. The quality improvements with outsourced
clinical trials may produce more effective, safer medicinal products. The quality
improvements made within the clinical trial processes may provide knowledge of the
quality of the drug and the adverse events associated with the medicinal product, which
may ultimately help the public understand the risks related to the medicinal product.
A Review of the Professional and Academic Literature
The purpose of this section is to provide a review of the literature to describe
various pharmaceutical challenges that are forcing pharmaceutical leaders to outsource
clinical trials to Asia Pacific, and to explain why quality breaks occur after signed quality
contracts. To understand this phenomenon, I conducted a literature review for clarity and
insight (Marshall, 2010). I provided critical analysis and synthesis of various sources of
literature such a government agencies’ reports, clinical regulations requirements, peerreviewed journals, books, and dissertations. Scholars addressed the pharmaceutical
outsourced clinical trial model and the various quality risks and concerns in the following
areas: (a) pharmaceutical challenges, (b) outsourcing, (c) top destination for outsourcing
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clinical trials, (d) outsourcing clinical business process, (e) outsourcing key risk factors,
(f) total quality management with pharmaceutical organizations, (g) quality of clinical
trials, and (h) clinical trials process improvements. For the professional and academic
literature in the doctoral study, the focus is to review peer-reviewed books, journal
articles, doctoral dissertations, and government websites. I used the Walden University
library databases to search for peer-reviewed journal articles, books, and dissertations.
Databases included ABI/INFORM Global, ProQuest, and SAGE Publications. I also used
Google Scholar to search for relevant literature. I employed the following search terms to
locate information: outsourcing in Asia, outsourcing clinical trials, outsourcing risks,
pharmaceutical challenges, quality systems, offshoring, general system theory, clinical
trial regulations, total quality management, and continuous process improvement. This
strategy assisted in identifying leading scholars and their studies. Integration of this
knowledge supported this study (Marshall, 2010). The literature review consisted of 95
peer-reviewed journal articles, government reports, dissertations, and books; 82 (86%)
were published within 5 years of the study.
The purpose of this qualitative case study was to explore strategies clinical quality
assurance managers use to avoid a breakdown in quality with outsourced clinical trials in
Asia-Pacific countries. The literature review supported the research study’s conceptual
framework and provided information regarding its application (Brown-Jeffy & Cooper,
2011). I used Ludwig von Bertalanffy’s (1968) general systems theory to understand the
complex problems of quality breakdowns with outsourced clinical trials.
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General Systems Theory
The conceptual framework for the qualitative case study basis was the general
systems theory. The general systems theory is a methodology employed to understanding
complex problems and phenomena. The concept of system science emerged due to the
response of individuals wanting to understand and deal with complexity. The system
theory started to emerge in the 1960s as a uniformed approach to understanding
environmental factors as well as humans and how they interplay with human
development and functioning (Germain, 1994). According to Laszlo and Kippner (1998),
the concept of the system theory is that the system is characterized by the interaction of
its components and knowing one part of the system allows information to another part of
the system. The approach drew upon the application of the human activity system as well
as the general system theory. Hall and Fagen (1956) defined the term environment in the
system theory any change to the subject or environment can attribute to systems changes
and the behavior. Germain (1994) described two system theories: the social system
theory and the general system theory. According to Germain, both system theories had a
common interest in the living system and could be used to view an individual as a
system. The difference between both system theories was the general systems theory was
from physical science, biologics, and cybernetics, and the social system theory derived
from social psychology, sociology, and symbolic interactionism (Germain, 1994). Ackoff
(1981) argued that the social system environment contained three purpose levels: the
parts of the system, use of the system, and the supra system.
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The general systems theory was founded in 1928 by von Bertalanffy; however, it
was not until 1968 that a true scientific breakthrough occurred with the publication of the
general system theory (Norlin & Chess, 1997). Von Bertalanffy grew quite dissatisfied
with the cause-and-effect theories to explain the change observed in living organisms and
decided to discover a definitive cause of a system relationship. Von Bertalanffy (1968)
searched to understand the order among the parts in the system, and not to focus on them.
Until this discovery by von Bertalanffy, a scientist focused on the reductionist process
based on linear causation to understand the whole system by examining the individual
parts, not how the parts related to each other (Norlin & Chess, 1997).
Von Bertalanffy argued that societies, organisms, and human organisms are open
systems. Also, von Bertalanffy explained that there are systems that have a number of
subsystem components that are interrelated and interdependent (Stacey, 2011). In an
organization, subsystem components related to the control and management information
systems and the cultures that kept harmonious teams working together. The general
systems theory recognizes that a whole system needs to maintain a form of control or the
subsystems will become out of balance over time. Inevitably, the system will be out of
balance with the environment as well as each other (Stacey, 2011; von Bertalanffy,
1968). However, adaptive mechanisms exist within an organization that promotes
changes and keeps it in equilibrium with the environment. Ultimately, there is an
inevitable conflict between the two subsystems; however, according to the general
systems theory, a successful organization will sustain equilibrium (Stacey, 2011).
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According to Stacey (2011), the general systems theory includes the following
organizational dynamics:


It is up to leadership to manage boundaries and to regulate the system, so
it adapts to changes.



Successful management will ensure the system adapts to the changes in
its environment and process negative feedback producing stable
equilibrium.



An organization is an open system, a set of interconnected parts that
interact with other individuals and organizations outside of it.



A system imports information and energy from outside itself, and
transforms both the energy and information in some way to export the
transformed results to a system outside itself.



Organizations should import systems by: (1) import across a boundary
separating it from other systems, (2) transform the imports within its
boundary, and (3) export back across the boundary separating the system
from the environments.



Success is state of harmony, stability, and consistency.



The relationship across the boundary is ever changing, the environment
will always change, and the boundary needs a regulatory function.



Adaption to the environment determines the stable equilibrium between
integration and differentiation, between the control system and
maintenance change required for success.
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As globalization developed, Godfrey (2010) asserted that interdependence becomes more
relevant and the complexity of the problems the organization needs to resolve increases.
Consequently, the organizational need for a sustainable environment is urgent (Godfrey,
2010). Organizations use a system thinking approach for these complexities.
Pharmaceutical managers use system thinking as a way to resolve complex problems and
designs. Essentially the framework for system thinking is to seek interrelationship rather
than things. Advantages for the organization using the system thinking approach include
leaders managing and grasping complex situations and uncertainty where there is no
simple situation. Godfrey (2010) summarized this approach as the practical holism when
the organization learns of an effective action by looking at connections rather than parts
separately (Godfrey, 2010). The three key framework ideas for the system are processes;
layers, parts, and wholes; and connections (Godfrey, 2010).
Quality Management Systems
In a clinical setting, it is difficult to measure quality. Quality systems require
implementation and development of standards within each step. Even though this
requirement is not new to clinical research, a systematic approach will produce more
reliable, high-quality data and a more useful product without compromising patients’
rights (Human Information Technology, 2014). There are several general requirements
that can improve quality systems such as training, personal roles and responsibility,
policies and procedures, quality assurance and auditing, document management, record
retention, reporting, and corrective and preventative action (Kleppinger & Ball, 2010).
Personal roles and responsibilities need to be communicated and documented for the
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clinical trial research team. It is essential for a clinical research team to create a
delegation log to create accountability for each member in the clinical trial. The
responsibility of training falls under the sponsor. It is up to the sponsor to ensure the
research investigator and clinical research staff are appropriately trained and qualified to
conduct a clinical trial (Collaborative Institutional Training Initiative (CITI), 2014). The
clinical research team needs mandatory training in good clinical practices and human
subject protection. It is essential that sponsors have policies and procedures in place to
approve a robust Good Clinical Practice (GCP) training to the research staff as well as
periodic refresher training. Food and Drug Administration (FDA) Regulations (2015) is
also in agreement with the training requirement within the quality system by stating in the
regulations when there is an investigational product within the clinical trial all key
clinical research personnel should be knowledgeable of all applicable regulations,
including those that pertain to human subject protections. Furthermore, it is also a
training requirement for the clinical research team to train on the clinical protocol and
document the training of the protocol. Finally, to ensure the adequacy of the training, a
knowledge test is highly recommended (FDA Regulations, 2015).
Before the investigator or sponsor writes any protocol, it is essential for the
investigator or sponsor to be well aware of his or her institution’s procedures and
policies. This can include, but may not be limited to, the handling of biological samples,
protocol review procedures, confidentiality agreements, human subject protections, data
management, and procedures for handling possible scientific misconduct (Code of
Federal Regulations (CFR) 21a, 2015). An essential policy for the institution to have is
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the record retention policy, which would specify a longer retention time frame than the
one required by the federal agency (CFR 21b, 2015). It is critical for institutions to have
written standard operating procedures (SOPs) in place for each clinical site.
Standardization with clinical research SOP templates is essential to provide quality
documentation standards within all clinical line functions (Clinical Trial Network
Business Practice (CTNBP), 2014). It is imperative that SOPs be reviewed periodically to
adhere to new regulatory requirements and updated processes and for all staff to
adequately document SOP training (CTNBP, 2014). Another critical component in the
quality system is to include quality assurance and auditing. Clinical trial teams are
familiar with a sponsor audit or a regulatory agency audit. Clinical trial teams are well
aware of the scrutiny of an audit when it comes to clinical database systems and quality
assurance procedures (Kleppinger & Ball, 2010). If there is no implementation of quality
assurance programs within the investigators’ sites, there is no quality oversight
(Kleppinger & Ball, 2010).
Other essential components of the quality system are document management,
record retention, and reporting. All staff should understand documentation of archival
procedures, and staff should demonstrate an understanding of these systems. Handling of
documentation such as tracking, filing, conventional naming, document version control,
and systematic backup of real-time data collection should follow standardized
procedures. All clinical documentation should be in a locked area with restricted access.
All computers should be qualified or validated, and password protected (Kleppinger &
Ball, 2010).
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The final component of a quality system is corrective and preventive action.
Clinical trial teams should document clinical trial quality breaks and corrective
preventative actions within the quality system to avoid any potential agency findings.
Potential problems will always arise in an outsourced clinical trial; however the discovery
of the potential issue should have an effective corrective and preventative action
assigned. After an allotted amount of time passes, clinical trial teams should perform an
effectiveness check to ensure the problem would not recur. According to Grignolo
(2011), the Clinical Trial Transformation Initiative, there are four key components
consisting of management responsibility, resource management, process management,
and improvement. Garza-Reyes, Rocha-Lona, and Kumar (2014) presented similar views
to Kleppinger and Ball (2010) that many organizations should turn to a quality
management system to provide high-quality products and customer satisfaction. RochaLona, Garza-Reyes, and Kumar (2013) argued that to obtain high-quality standards,
organizations need to integrate the quality management system and deploy quality
management tools and methods across the whole organization. Garza-Reyes et al. (2014)
had slightly different elements of their quality management system (QMS) and
categorized them by processes, human capital, business strategy, information technology,
and management models-methods-tools. To have an effective quality management
model, tools, and methods; organizations refer to the ISO guidelines, six sigma, lean and
business techniques, total quality management (TQM), process re-engineering and
business excellence models (BEMs) (Asif, Searcy, Garvare, & Ahmad, 2011; GarzaReyes et al, 2014). When organizations develop a well-structured integrated QMS, it
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provides a competitive advantage for customer satisfaction and higher quality products
(Asif et al., 2011; Garza-Reyes et al., 2014; Jones, Parast, & Adams, 2010; Kanji, 1996).
Some of the gaps that existed in the quality management literature were that the
authors did not discuss the effectiveness or non-effectiveness of the quality management
system through quality metrics. If the authors discussed, quality metrics within the
literature for quality management system, they would provide the audience knowledge on
organization performance. In addition, there was no discussion on what the common
reasons were that breaks occurred in QMS, even though the organizations had the
appropriate total quality management model.
Quality Management System Within a Pharmaceutical Organization
Quality is an essential component of the pharmaceutical industry. Johnson and
Gupta (2013) defined quality as providing practical solutions to the queries about the
profits and dangers of a drug process while guaranteeing safety for human subjects. To
fulfill the regulatory requirements, the sponsors need to enhance quality by improving
systems and processes (Cerullo et al., 2014; Hanfield & Gosh, 2004; Johnson & Gupta,
2013) with definite standards for every clinical test procedure. It is mandatory for the
sponsors of clinical trials, business process organizations, and contract research
organizations to establish, maintain, control, and monitor both the quality assurance and
quality control systems. In addition, for organizations that follow the systems’ standard
operating procedures and other clinical quality documents provide the highest quality
product and services to meet customers’ needs and expectations (Johnson & Gupta,
2013). For a clinical study to have quality, it must include an experimental design that is
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scientifically and ethically sound; protection of the subjects’ rights, safety, and welfare;
competent personnel; adequate surveillance; and current, complete, and exact data. In
recent years, regulatory agencies have become stricter on clinical trials specifically
regarding patient security and data credibility (Johnson & Gupta, 2013). According to
Johnson and Gupta (2013), the main purpose of the regulatory agencies is to execute the
principles of quality management in health research to impede downfall, maximize the
use of valid resources, and guarantee consistency and dependability of outcomes.
Quality management system success factors Pharmaceutical organizations
utilized quality management systems to improve the quality of product and process to
achieve continuous customer satisfaction (Khanna, Sharma, & Laroiya, 2011).
Implementation of quality remains an important issue for global organizations, which are
continuously trying to improve their competitiveness (Khanna et al., 2011; Johnson &
Gupta, 2013). The R&D organizations are facing an evolving environment, which is
rapidly changing due to globalization. Indian R&D organizations specifically are in dire
need for new approaches, strategies, and techniques to have a competitive advantage
(Khanna et al., 2011). One question asked by many organizations (Khanna et al., 2011;
Johnson & Gupta, 2013) is why with the implementation and benefits of quality
management systems do many Indian R&D organizations face numerous implementation
problems? Quality management remains a challenge because the decision makers within
the organization are not prioritizing critical success factors. For an organization to adopt
new quality management systems, produces high risk due to the high cost associated with
adoption. One of the standard practices in India is to select training and then adapt to
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process carefully using various methods to reach the final decision. In order to achieve a
competitive edge, organizations have shifted priorities from a low-cost production to
quality, dependable delivery, flexibility, and short lead-time. They also implemented new
philosophies and information technology such as quality management systems, Six
Sigma, lean, business process re-engineering and business excellence models, which
claims to support an organization's improvement efforts (Thawesaengskulthai and
Tannock, 2011; Khanna et al., 2011). Indian organizations realized that they would not
gain competitive advantage without being quality conscious (Khanna et al., 2011). The
quality management system implementation depended on several factors such as
communication, management commitment, and employee involvement (Kanji, 1996).
Quality management system critical success factor For QMS implementation
to be effective within the organization, it involved the defining and deploying critical
success factors (CSF). These factors included the hard factors such as systems, tools, and
techniques, as well as, soft factors such as employee commitment and leadership (Khanna
et al., 2011). The CSFs are the factors that can significantly affect the organization and
required particular attention in the quality management systems. The CSF provided signal
detections of early warning risks within management systems and avoids any surprises.
In order for the successful QMS implementation, the organizations should have a
thorough understanding CSFs and adoption of the QMS implementation (Salahedin,
2011; Khanna et al., 2011). One of the key points in the literature reviews (Khanna et al.,
2011, Salahedin, 2011) is the ranking of the CSFs in the quality management
implementation to reduce costs, increase success rate, and prevent failure.
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Top management leadership is a vital factor because it is important for
management to provide enough resources to ensure quality achievement, as well as,
understand the concept of quality and importance of it. Management needed to
understand and identify quality management goals and demonstrate understanding those
objectives. One of the gaps in management leaders is their lack of intention of the quality
management system. As well as, how it is implemented in various line functions within
the organizations (Khanna et al., 2011). The second CSF is supplier quality management.
Supplier's management focused in on the effectiveness of the quality management system
within the organization. The relationship between supplier and organization is an
important relationship to maintain (Khanna et al., 2011; Salaheidin, 2011). In order to
have an active relationship, the organization had few supplier rather than many suppliers.
There should be a clear understanding of each other expectations and each other's
processes to ensure quality products. The organizations’ expected proper quality
management systems in place to measure/monitor delivery performed and quality of the
product and has knowledge information exchanges with the supplier on the regular basis
(Khanna et al., 2011). The third factor is process management. Process management
should meet the criteria of the international organization for standardization (ISO) 9000
standards (Khanna et al., 2011; Candido & Santos, 2011). Frequent reviews of all aspects
of clinical and manufacturing operations should be down and any corrective and
preventative actions implemented. The identification of key processes and improved
continuously to achieve higher quality with the product (Khanna et al., 2011). The fourth
CSF is human resource management. Human resource management focus is to empower
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employee management within the organization. Human resource management
encouraged employees to innovate and contribute quality continuous improvement
processes (Khanna et al., 2011). Quality management within pharmaceutical organization
focused on an open quality culture, teamwork, and having sustainable continuous
improvement. Quality management required human resources management systems to be
in place to support this focus. The systems allowed information exchange between human
resource and employee to ensure that employees are aware of the role and
responsibilities, goals and objectives, and job training. The fifth CSF is customer
satisfaction. Customer satisfaction in quality management focuses on the quality measure.
The more satisfied the customer, the greater the quality measure. Organization should
have systems in place to receive complainants and feedback. The sixth factor is the role
of the quality department within the organization. The quality assurance department
should have clear objectives, vision, missions, systems, quality policies and tools in place
to implement a viable total quality culture (Khanna et al., 2011). The seventh factor is
training. Training places a crucial role in the implementation of the quality management
system. Khanna et al. noted quality management system key focus is adequate training
and education of employees to improve their knowledge and skills. It includes general
training as well as specific training and retraining of the employees. It provides a base for
communication of new organizational strategies to the employees. The eighth factor is
quality citizenship. Quality citizenship is when the organization adopts an ethical
standard that allows the accountability and transparency of key stakeholders for their
organizational performance. They promote both social and corporate responsibility and
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environmental sustainability both in the present and the future. The ninth CSF is a quality
system and information technology. To collect information on data such as cost of quality
data, scrap data, and rework data; an effective and efficient system should be in place.
The information system should enable data be transparent, collected in a timely manner,
and provides feedback to the employees. The outputs of these systems allowed to
measures quality performances (Kanji, 1996). The use of IT has a profound effect on
quality managements by contributing to the enhancement of quality awareness, reduction
of quality costs, improvement of product and processes. Finally, there is the product
design. Product design is an important factor in the quality of the product. Product design
must meet with quality standards, ethical standards and meet with regulatory
requirements (Johnson & Gupta, 2013). Product design ultimately effects if the product to
the customer is right or wrong and if it will meet the customer satisfaction. Johnson and
Gupta, Khanna et al., and Saleheldin discussed quality management systems,
implementation, and the success factor, which will assist organizations to succeed in
implementation. However, one gap that exists, there is no detailed discussion of
unsuccessful factors that causes the quality breakdown with quality management systems.
By addressing both successful, and unsuccessful factors provides the reader a
comparative to understand why the factors were categorized success and unsuccessful.
Quality management system implementation barriers One common failure
factors of quality management system within an organization is improper implementation
(Cândido & Santos, 2011; Dahlgaard-Park, 2011; Hoonakker, Carayon, & Loushine,
2011; & Kanji, 1996). Many organizations’ find it difficult to effectively implement
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quality management systems, which in turn have lost the momentum to adopt an efficient
model and instead have only set quality management system initiatives (Cândido &
Santos, 2011; Manjunath, & Kumar, 2013). Due to the difficulty of implementing quality
management system, there is a decline rate within many organizations in adopting quality
management systems (Cândido & Santos, 2011; Dahlgaard-Park, 2011) and instead are
turning to other management strategies such as ISO 9000 management strategies
(Cândido & Santos, 2011). There is a common theme among the literature review by
authors Cândido and Santos, Dahlgaard-Park, Hoonakker et al., Kanji, Manjunath and
Kumar, and Moballeghi (2014) agreed the reason for failure of many organizations
quality management system models is that it requires total quality cultural change for
everyone within the organization. In addition, there is also agreement that top managers
and executive leaders need to take an active leadership role have the commitment from
everyone within the organization committed to the quality goals.
Sebastianelli and Tamimi (2011) acknowledged additional factor analysis of QMS
barriers, which reveals five common obstacles such as lack of customer focus, inadequate
resources of QMS, inadequate human resources development and management, lack of
quality planning, lack of leadership for quality. As well as, provided framework for
evaluating the significance of top management related obstacles for QMS success, as well
as, provided additional guidance in developing strategies for a complete and effective
QMS transformation (Sebastianelli & Tamimi, 2011). Yusof and Aspinwall (2011)
introduced other QMS barriers, which are not mentioned by other authors such as training
and development of staff at ad hoc can hinder improvement effort. In addition, the lack of
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financial resources, this can affect organizational processes as well as management not
delegating a task, which can stifle teamwork. All of the elements above can hinder QMS
implementation, and there is a vast literature on how QMS can help to improve the
quality and how difficult it is to implement. However, there is scarce current works of
literature that provided a framework for organizational leaders to develop strategies to
have an effective QMS in their outsourcing the models in developing countries
(Moballeghi, 2014). A gap in the literature it does not discuss the difficulties that
developing countries have in identifying QMS barriers and critical success factors of
QMS implementation (Moballeghi, 2014). As the trend to outsource to developing
countries is becoming part of many global organizations, the focus for future studies on
how to implement a successful QMS implementation. Furthermore, the study’s aim of
proper guidance to benefit manager within these developing countries where there is a
lack of information on how to overcome these implementation barriers and can promote
new systematic way of thinking in various cultural context (Moballeghi, 2014). One of
the gaps in literature is there is no analysis of what an organization does after identifying
QMS barriers. There is no clear guidance for an organization to remove a QMS barrier.
The final gap in the literature is QMS success factors are implemented within the
organization; however, sustainability is not discussed (Asif, Searcy, Garvare, & Ahmad,
2011). I think if future studies address these gaps in the literature more global
organizations will have the tool and skill set to implement and sustain an effective QMS
model.
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Pharmaceutical Organizations Challenges
Pharmaceutical organizations are faced with various challenges that relate to
regulations, advance in technology, globalization, product competition, innovation of
new knowledge, and outsourcing (Duppada & Aryasri, 2011). Outsourcing clinical trials
is the biggest trend of pharmaceutical business approach to gain the competitive
advantage, to gain quicker regulatory approval, and to produce efficient and effective
clinical trials by outsourcing organizations (Kara, 2011; Sharma, 2010). Pronker et al.
(2011) agreed with Kara that due to the drug price increase the supply chain is under
scrutiny. The drug pipeline is decreasing, and the cost of drug development is increasing.
Consequently, this is leading to more out of pocket expenses for patients for drugs. The
increase of drug development costs and having a competitive advantage is leading
clinical trials and research development functionality to outsource to India.
There are vast amount of peer-reviewed literature, which analyzed the challenges
that pharmaceutical organizations face. Hafner and Popp (2011) and Lamittina (2012)
discussed some these challenges, such as tremendous amount of the financial loss to other
generic organizations when patent expires. For example, the top ranked pharmaceutical
companies such as Bayer lost its patent rights to Nexavar, Roche lost patent for Tarceva,
and Pfizer denied the patent rights to Stuten and lost billions of dollars. The effect of the
tremendous amount of financial loss causes the pharmaceutical company to consider
outsourcing.
Pammolli, Magazzini, and Riccaboni (2011) agreed that the pharmaceutical
organization specifically in research and development are facing tremendous challenges.
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One of the challenges the R&D organization face is complexity in the productivity of the
pipeline. Pharmaceutical R&D productivity from the mid-1990 has experienced a
downturn. From 1998 to 2008, the number of new molecular entity approved per year as
declined. According to recent estimates, the average time to pass approval through US
clinical trials ranges from six years to eight years (Pammolli et al., 2011). Innovation in
pharmaceuticals is a cumulative process, and, unfortunately, the markets where effective
compounds are available there is high POS. In the established markets, the patent
innovates drugs are at the same level as the older drugs. Consequently, R&D investments
tend to focus on new therapeutic targets, which are characterized by high uncertainty and
difficulty, but lower expected post-launch competition (Pammolli et al., 2011).
Adobor (2012) also agreed on the increasing challenges such as increasing speed
in drug development, domestic cost increase, various challenges of competition,
emerging markets, global clinical sponsors, outsourcing critical parts of the value chain
activities specifically drug testing and contract clinical organization is causing ethical and
moral issues. There are advantages for pharmaceutical giants to outsource medical
research for lower cost to Asia Pacific. However, the contract medical research that is
being outsourced is in jeopardy until the ethical issues and concerns associated with
outsourcing business models are not being addressed or recognized. One gap in the
literature is there is discussion on challenges that pharmaceutical organizations face,
however, there is no discussion in the literature on how the challenges affect the
pharmaceutical organization such as employee morale, loss of jobs, adapting to new
culture and technology.
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Drug development costs According to Rosier, Martens, and Thomas (2014), the
estimated cost of the drug development can range from 800 million US dollars to 1
billion. Investments for pharmaceutical companies in the development of new drugs is a
considerable risk, due to the fact it is unknown if the new drug is safe in patients until the
end of drug development (Rosier et al., 2014). American's spend $2.6 trillion dollars on
healthcare last year (Hassanzadeh, Modarres, Nemati, & Amoako‐Gyampah,2014) and
the healthcare expenditure shows over 12.9% of total expenditures is with the
pharmaceutical and it is the fastest growing portion of healthcare spending (Hassanzedeh
et al., 2014). There is an agreement between the authors this is at the increasingly high
prices of prescription drugs, especially with specialty drugs and brand names, and rising
associated costs with research and development of new drugs. Pharmaceutical
organizations argue the rise of cost is due to the fact the process of drug development in
R&D is extremely expensive and requires substantial capital expenditure (Hazzanzedeh
et al., 2014; Drain, Robine, Holmes, & Bassett, 2014). For a pharmaceutical organization
to make a cancer drug, it cost them around $1.75 billion for R&D and almost ten years to
grow through the various test and market. American pharmaceutical organizations alone
spend over $45 billion on developing new drugs or modifying current drugs.
Outsourcing
For the pharmaceutical organization to meet the challenges of increasing cost of
drug development and stricter regulation, they are turning to outsourcing clinical trials.
Outsourcing consists of operation functions or transferring of internal functional services
to a third party service provider and controlling the sourcing through the partnership or
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contract management (Mariani, Falotico, Zavanella, & Mussini, 2014). A vast amount of
literature provided the benefits and motivations for pharmaceutical organizations to
outsource. The three major reasons for motivation for outsourcing are target health
policies, public health development strategies, and public spending cuts (Mariani et al.,
2014). Outsourcing does provide potential benefits, however there are also several
disadvantages ( Mariani et al., 2014; Roberts, 2001; & Sharma, 2010 ) cost savings is
lower than expected and not available over the long term; liability for vendor action,
being over-dependent on vendors and losing control over the standard of service
delivering (Mariani et al., 2014).
The outsourcing of various functional departments within R&D, to CRO or BPO,
is a frequent practice (Huysmans et al., 2014) among pharmaceutical organizations to
lower costs and achieve faster approval timelines. However, the majorities of the
outsourcing projects are prone to failure (Huysmans et al., 2014) and increase costs for
pharmaceutical organizations to repair the damage. Due to the high risk of failure, many
scholars suggest a variety of outsourcing risk factors that leads to unsuccessful project
outcomes, as well as possible remedies to mitigate them. There are many empirical
studies, which continue to report frequent failures in outsourcing projects. Huysmans, De
Bruyn, Beazeer et al. (2014) used the concept of modularity for an alternative perspective
to analyze risks related to outsourcing projects. The approach assisted in supplementing
existing outsourcing risk analyzes with new, additional, or more profound insights into
outsourcing risks. In addition, it served as an additional basis to list a more exhaustive
enumeration of required mitigating actions, which leads to successful outsourcing
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projects (Huysmans et al., 2014). In the BSkyB, the case showed the alternative
perspective that illustrates a reanalysis of a failed outsourcing case documented in the
literature and available court proceedings. According to Huysmans et al. the BSkyB case
shows the specific way how the poorly designed modular structures at the project
communication, technical, and project management level could identify ex-ante. The
identification explained the manifestation of ex-post outsourcing risk factors such as
managing user expectation, lack of required skills, managing user expectation,
communication problems, project management, and significant integration requirements.
Top destinations for outsourcing clinical trials The author Langer (2011)
provided an in-depth analysis of benefits and risk to outsourcing to India and China from
the intellectual property. The comparison of the large pharmaceutical companies of the
research and development spend provided excellent data on how much each company is
spending on R&D costs. The author slightly touched on the quality aspects, however not
much detail or analysis on the breakdown of the quality and the recovery from it. Surve
and Tembhurne (2013) drew the same conclusion as Langer that India and China are the
top destinations for outsourcing. Surve and Tembhurne discussed how the trend for
pharma and life sciences industry is favoring of outsourcing both research and
manufacturing to India. India became the most sought out destination for outsourcing due
to low cost (Drain et al., 2014). Frost and Sullivan (2011) study results showed India's
contract research and manufacturing estimated at $895.44 million in 2006 and increased
43 percent over the previous year. Clinical research currently is 16% of their revenue.
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The leading driver to outsource clinical trials to India costs and compliance issues are
becoming prohibitive for them in the West.
Novak, Beloserkovsky, and Payeur (2014) acknowledged there are changes in the
geographical regions in the global clinical trial landscape. The reasons for increase global
clinical trials: (a) increased prevalence of chronic diseases, (b) aging population, (c) the
embrace by physicians and payers of evidence-based medicine, (d) and patient's common
belief that they will benefit from treatment and medical technology, and (e) access to
medical treatment through participation in clinical trials (Novak et al., 2014). The newly
growing regions for clinical trials have moved to East Asia, and South Asia is the fastest
growing regions. A great hike has registered with China by +30% and South Korea by
+29%. Both countries represent almost +7%. India has the most significant growth at
40% due to the considerable advantages such as the acceptable quality of services and
good patient recruitment (Novak et al., 2014).
A recent research study conducted by Yathindranath, Kureishi, Singh, et al.
(2014) in the evolution of clinical trial landscape of Asia Pacific explores the increase in
global trials in the region. The method used for the study was an extraction of clinical
trial data from 15 commercially available online databases for global clinical sites and
trials including Asia registries. The clinical trial registries such as: Australian New
Zealand Clinical Trials Registry, ClinicalTrials.gov; the International Standard
Randomized Controlled Trials Number; Clinical Trials Registry, India; Clinical Research
Information Service, Republic of South Korea; Japan Primary Registries Network; the Sri
Lanka Clinical Trials Registry assisted with gaining access to the data (Yathindranath et
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al., 2014). In order to analyze the latest trends in Asia Pacific, two-time periods (20092010 and 2011-2012) were collected. The results from the study showed that in
comparison of the two-time periods Asia Pacific is stable with the volume of clinical trial
site numbers and clinical trial numbers. The primary destinations for agencies inspections
there are the change in geography, therapeutic areas of clinical trials observed and
conducted. The study concluded the top ten destinations in Asia Pacific for major clinical
trials destinations are Taiwan, Japan, South Korea, India, and People's Republic of China
(Yathindranath et al., 2014). The rising standard of medical care and the standard of
living in developing countries such as Vietnam, Philippines, and Indonesia is causing an
increase in local clinical trials.
The major component of the increase in global drug development is the
emergence of Asia. Asia is still in the infancy phase when it comes to the perceived
potential in the pharmaceutical industry; however, growth is steadily increasing. The
reason for growth is due to the financial consideration of the clinical trials such as
reduced per patient costs and shorter recruitment timelines, which are primary drivers of
the growth (Horsburgh et al., 2014). One of the active contributors to the growth of
clinical trials in Asia Pacific is oncology. The rapid growth in Asia Pacific is due to the
total investigator site pool, as well as, the number of experienced and inexperienced or
naïve sites, which are being, activated (Horsburgh et al., 2014). In April 2013, more than
9,000 ongoing clinical trials in Asian Pacific countries were listed in the
ClinicalTrials.gov database, 20% of the global clinical trial landscape (Horsburgh et al.,
2014). Twenty-seven percent consisted of Asian-Pacific studies were Phase I, Phase II or
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Phase III oncology trials. Additionally, less than 10% of all patients enrolled during the
observed period were involved in oncology studies.
Outsourcing clinical business processes. Pharmaceutical organizations
increased sourcing their clinical business processes through third party service providers,
a standard practice known as BPO. Globally, the BPO market earns $279 billion dollars
in their clinical trial services, and it will continue to grow at 25% annually (Lacity,
Solomon, Yan & Willcocks, 2011). In the last 15 years, many academic researchers
studied this market and produced findings relevant to practice. In previous research,
many outsourcing vendors have been reviewed; however, the entire body of BPO
research has never been considered. Lacity et al. conducted a study to fill this gap. The
research consists of total studies and reviews 87 empirically robust BPO articles
published between 1996 and 2011 in 67 journals to answer three research questions:
What has the empirical academic literature found about BPO decisions and outcomes?
How do BPO findings compare with Information Technology Outsourcing (ITO)
empirical research? What are the gaps in knowledge to consider in future BPO research?
The study provides researchers of a broad overall broad understanding of BPO. However,
the BPO practice continues to evolve as more pharmaceutical clients and suppliers on
every continent are actively participating in the global sourcing community. One gap that
remains is a quality of the BPOs’ clinical trial processes provides for their pharmaceutical
client.
Lahiri, Kedia, and Mukherjee (2011) agreed with Lacity et al. (2011) there are
significant gaps in the understanding the context of the offshoring service providers.
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However, even though there are gaps in the research on understanding BPO as a whole,
many organizations still outsource their business processes. Essentially, organizations
disaggregated their value chain and transition over their parts to the providers for a
successful delivery and execution of the processes. The primary inspiration for an
organization to move to BPO is cost savings, adding flexibility of business operations,
greater risk spreading, increased focus on core business activities, and reduced to market
(Lahiri et al., 2011). For BPO to partake in the rapidly growing market, they offer a wide
variety of value-added services to their expertise. BPO are no longer providing
information technology services, banking, and capital market, mortgage services,
however now extended to include clinical trial services. Pharmaceutical organizations
tend to contract with BPOs for their clinical trial services. The BPO contracts are longterm in nature than in traditional offshore outsourcing contracts requiring business
partners to remain focused on building and sustaining value-creating relationships (Lahiri
& Kedia, 2009). One gap with BPO that remains is the lack of understanding their quality
as an ongoing business partnership.
Scholars suggested that the quality of ongoing business partnerships needs to be
high to enable collaborating organizations to realize valuable outcomes (Lee, 2001). The
partnership quality is how well the partnership delivery outcomes match the participants’
expectations. According to Lee, the current context of partnership quality refers to the
perception of the extent of fulfillment of expected outcomes arising out of the interorganizational relationship between provider and client. Prior research (Lee, 2001) shows
that partnership quality as a valuable relational resource allows providers to perceive
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nature of their cooperative relationships with clients, as well as, encourage them to
consider ways to enhance or strengthen the same in order to perform better. Lee
suggested the knowledge might enable providers to gauge their ongoing partnerships on
various parameters such as compatibility with policies and culture, sharing benefits and
risks, business understanding, and dependability. In addition, if there is such an
understanding, providers are in a position to enhance performance by escalating
commitment, coordination, and trust, increasing flexibility in accommodating changes,
and considering clients as business partners and not just customers of services (Lee,
2001).
One of the top destinations for BPOs is India. Dzever and Gupta (2012) agreed
the BPO is extensively growing and one of the sought out BPO destination is India due to
the observation of clients that the BPO industry in India people work 'when the rest of the
country sleeps'. There is the majority of BPO in India accommodates and work the
European and USA time frames. Therefore, meaning most BPO employees in India work
the night shift or the graveyard shifts.
Outsourcing key risk factors As the outsourcing trend continues to rise, it is
important for the organization to consider potential risk factors that occur when
outsourcing and the importance of having a risk framework before signing any contracts
with outsourcing vendors or BPOs. Critical risk factors to a client are associated with
financial, complexity, contract, execution, legal, planning and control, the organizational
environment, scope and requirements, the user and team (Alaghehband, Rivard, Wu, &
Goyette, 2011). One of the important risk-based decision-making factors would be the
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regional location of the outsourcing organization. The more information the organization
has on the outsourcing region's geopolitical instability and economic volatility the lower
the risk (Holbrook, 2011).
Gholami (2011) conducted a qualitative study to determine the critical risk factors
when outsourcing IT projects. The results showed the five key risk factors are financial
risks, technical risks (such as database, communication infrastructure, software risk,
security, and licensing), managerial risk, behavioral risks, and legal and political risks
(Gholami, 2011). One of the common mistakes that senior management make in the
outsourcing business model is not having the understanding or having the knowledge of
the risks, the right tools to handle the risks and developing an effective mitigation for the
risks (Ghandi, 2011 & Gholami, 2011).
One of the main reason organizations benefit from outsourcing is a reduction in
cost, however when outsourcing processes to offshore location increases strategically
risks as a result of vendor to clients deliberate actives (Gholami, 2011; Liu & Nagurney,
2011). Organizations need to conduct a quality assessment as part of the determining
factor in choosing the most appropriate vendor that the organization determines has the
quality and the right equipment (Yu & Thomas, 2011). Ghandhi (2011); Gholami,
(2011); He, Weeks, Buyske, et al.(2011); and Yu and Thomas, (2012) agreed when
choosing a vendor for long-term business process a vendor assessments are key.
Pharmaceutical organizations’ need a complete understanding of the vendor
organizational structure, trading relationship, operational manager, general management
practices, quality culture and understanding their financial for successful projects. The
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most common vendor risks during a quality assessment are knowledge transfer, lack of
active vendor management, incomplete contracting trust (Hamlen & Thuraisingham,
2012).
Organizational management’s awareness of offshoring BPO’s cultural risk factors
that often occur with client/organization and vendor relationships (Holbrook, 2011;
Mosher & Mainquist, 2011) can alleviate future problems. Culture plays a significant role
when dealing with offshoring vendors. Communications, management style,
understanding each other culture, gender issues, quality management, and team harmony
are at risk if client and vendor have serious communication break (Holbrook, 2011).
Quality of Clinical Trials
With the developments of global markets quality has become the central focus.
Previously, many companies have forgotten to include quality as part of their strategic
objectives (Devpura, Garza–Reyes, Kumar, Rocha–Lona, & Soriano–Meier , 2014).
However, now quality measurements and quality performance are the key focus of
numerous companies in the global markets. A single case study conducted on a
multinational Fortune 500 pharmaceutical company who has built a conceptional quality
model in their strategic objectives to explore how quality model affects their processes
(Devpura et al., 2014). The results showed a company who had a total quality
management built into its model earlier showed greater global competition, advanced
programs, and effective quality processes. In addition, European companies include the
ISO 9000 criteria for a quality model and emphasis on the quality culture were the
highest marked for their quality products (Devpura et al., 2014). When research
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organization conduct clinical trials, it is important for them to adhere to good clinical
practices. Adhering to these practices will help to avoid an audit finding from sponsor
and health authority agencies (Karbwang, 2013).
One major need for consumers is for a drug developed by the pharmaceutical
organization to provide safe and effective therapeutic drugs to promote, cure, and treat
diseases, as well as, health and prevention (Sasaki, McGibbon, Lee, Murray, & Pharr,
2014). The pharmaceutical organization’s ability to consistently deliver these products
declined in the last few years due to job losses, site closures, an increase of R&D costs,
and productivity lags (Sasaki et al., 2014). Due to the decline, pharmaceutical
organizations are finding alternate methods to produce consistently and deliver products
with the decrease in cost. Pharmaceutical organizations are turning to CRO and BPO in
Asia Pacific to reduce drug cost and approval. However, one question arises, what quality
measures or steps are taken to provide a safe and effective drug? In recent years, both the
FDA and European Medicines Agency (EMA), identifies the significant limitation of
clinical trial oversight conducted by pharmaceutical organizations. An example of lack of
clinical trial monitoring were illustrated when Johnson & Johnson, Pfizer, and ICON,
received FDA 483 warning letter for significant lapses clinical trial oversight (Cerullo et
al., 2014).
India is similar to many other countries in the division of their medical regulatory
structure between national and state authorities (Sackman & Kuchenreuther, 2014). The
national authority for pharmaceutical regulations in India is known as The Drug
Controller General of India (DCGI). The responsibility of the DCGI is to approve new
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drugs, import drugs, and biological in selected category, approval of clinical trials and
quality standards in the country. Sackman and Kuchenreuher agreed with FDA on the
DCGI quality standards especially due to the citing quality-control problems ranging
from data manipulation to sanitation. Due to concerns of the quality issues associated
with the clinical trials the FDA and other regulatory bodies have increased inspections of
Indian plants in response to the high amount of outsourced clinical trials being conducted.
Pharmaceutical organizations are reassessing their Indian outsourced contracts with these
plants and giving careful consideration to moving forward with developing new strategic
partnerships (Sackman & Kuchenreuther, 2014). There are high concerns with data
quality and data integrity, which impacts manufacturers' perception of India's clinical
trials system. India became the most sought destination for the pharmaceutical
organization for clinical trials due to the large and diverse patient pool, as well as, low
drug trial costs makes the country an attractive. However, India has recently seen
increased number of clinical trials fall dramatically due to allegations of noncompliance
to protocols and organizations taking advantage of disadvantaged patients (Sackman &
Kuchenreuther, 2014). Hanfield and Gosh (2004) and Sackman and Kuchenreuther
agreed that due to noncompliance response manufacturers are forcing to either to move
their trials to another country or encounter significant delays in clinical trial approval,
which is ultimately holding their organizations back.
For clinical trials to have the highest quality, it must adhere to good clinical
practice (Cerullo et al., 2014; Handfield & Ghosh, 1994; Johnson & Gupta, 2014;
Sackman & Kuchenreuther, 2014). GCP is defined as an international scientific and
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ethical quality standard for conducting, designing, recording and reporting trials that
involve the participation of human subjects (ICH, 2015). According to ICH, clinical trials
must be compliant with GCP guidelines to ensure the protection of the rights, safety, and
well-being of the research trial subjects, as well as, ensuring data integrity. The principal
objective of the GCP guideline is to provide a unified standard for current good clinical
practices amongst the European Union (EU), United States, and Japan to have quality
standards and mutual acceptance of clinical data by the regulatory federal agencies within
their jurisdictions (ICH, 2015).
Adherence to GCP is the essential quality criterion for conducting clinical trials.
The GCP standard practice applies to all parts of the clinical trial process. Pharmaceutical
or any research and development organizations that do clinical research needs to build
GCP requirements into their clinical trial processes to ensure quality in a clinical trial
(ICH, 2015; Johnson & Gupta, 2013). Under the GCP guidelines, the quality of the
clinical trial is a continuous sequence, which commences with designing, conducting,
recording, and reporting of the clinical trials (Johnson & Gupta, 2013). Compliant with
the GCP quality standard throughout the clinical trial conduct guarantees that the data
reporting analysis results are credible and reliable, as well as, ensures the rights, safety,
and well-being of the human subjects.
Consequently, even though there is no change to ICH GCP (2015) guidelines over
the years, adherence to these principles have become more difficult to attain, due to the
changing scenery of conducting the clinical trials (Johnson & Gupta, 2013). Lad and
Dahl (2013) shared a similar concern for the role quality plays in clinical trials and
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processes. Despite the acknowledgment of importance that is placed on quality assurance
in the clinical research process and clinical trials, there is still a high-level concern for
quality assurance program implementation in foreign academic teaching hospitals or a
similar institution. Even though, the fact that quality assurance is expected in such
programs that certify and accredit Institutional Review Boards (IRBs), very little is
known about the role of the IRB in programs of clinical research quality assurance. In the
IRB programs, clinical quality assurance needs to be defined, and processes placed in
achieving quality assurance (Lad & Dahl, 2013). According to Lad and Dahl, essential
elements of the quality assurance program are continuous education and training at site
level, as well as, auditing and monitoring program, which reinforces the understanding
and knowledge of quality assurance.
In order to measure the quality of a clinical trial, an audit needs to be conducted to
ensure adherence to the clinical protocol, sponsors' clinical trial process, and clinical
regulations. One of the quality breakdowns in a clinical trial process is the auditing of the
informed consent (Lad & Dahl, 2014a). An informed consent is one of the essential
clinical documents for clinical trials and can be defined as documentation, which informs
the clinical trial participant about the clinical trial and the risks and benefits associated
with the clinical trial, as well as any unforeseen risks associated with the clinical trial.
Informed consent emphasizes the clinical trial participants’ rights and volunteer
participation in the clinical trial (Lad & Dahl, 2014b). An audit of the informed consent
should be conducted to ensure adherence to the federal regulations requirement. The
informed consent is a signed documentation from the voluntary participants to participate

43
in the clinical trial process and documents the conversation between the sponsor and
voluntary participant in the clinical trial. Sponsor’s conducting audit of the informed
consent will help to ensure better alignment to the clinical protocol and federal regulation
and will help ensure less scrutiny of regulatory agency inspections and IRB.
Clinical Trial Process Improvement
The data from this study might impact social change by providing awareness,
knowledge, and risks associated with quality breakdowns when the pharmaceutical
industry is outsourcing R&D. Outsourcing R&D caused negative relationships with
pharmaceutical companies employees with the outsourcing employees (Mendivil, 2012).
Due to outsourcing, internal resources are being laid off; morale is decreasing, and
strained resources. The research data may provide insight to the leaders the effects it has
on their internal employees and how to improve and build a better relationship with
internal resources and outsourcing associates (Mendivil, 2012). Furthermore, it may also
provide ways to enhance business practices and the conduct of an outsourced clinical trial
quality to bring the safest most effective medicinal product to patients faster.
According to Paul (in press), there is an extremely competitive race for a
pharmaceutical organization to bring the first new drug therapy to the market. The
pharmaceutical organizations’ face increasing challenges such as drug cost pressures,
difficulties in obtaining patient recruitment, and drug target population. Even when the
pharmaceutical industry meets its challenges, there is always an unexpected regulatory
finding of the testing procedures and quality of the trial, which can derail an entire
clinical program. The last decade global regulatory agencies have been placing increased
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scrutiny on clinical data quality. Due to the increased regulatory scrutiny, there is a
stimulus for the development of more effective and consistent quality management
systems (Paul, in press).
Jones, Parast, and Adams (2010) have a similar view to Mendivil (2012) and Paul
(in press) however, a different approach to how to improve process improvements while
organizations are facing challenges. Jones, Parast, and Adams argued that process
improvement initiatives do not always provide the best results; however, organizations
need to frame it within the systematic process improvement structure. Emphasis on
elements such framed within a systematic process improvement structure. Elements
vision, skills, resources, action plans, and incentives are necessities to have an effective
six-sigma implementation (Jones, Parast, & Adams, 2010). A deficiency in any of the
above stages of process improvement will have an adverse effect on the desired outcome
of any project. Similarly, Wong, Tseng, and Tan (2014) agreed to boost organizations’
performance they need to configure business process model in order for the team
performance to improve continuously.
Transition
The purpose of this study was to explore one pharmaceutical organization’s
clinical quality assurance management team’s knowledge and experience of the quality
management system breaks when outsourcing clinical trials to Asia Pacific. The in-depth
description data lead to highly successful outsourced clinical trials. In the literature
review, I discussed various components of the general systems theory, quality
management system, clinical trials processes and regulations, outsourced clinical trials,
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current challenges that pharmaceutical organizations are facing and discuss the decision
to move to an outsourcing model, as well as, discussing the risks and benefits of
outsourcing clinical trial to the top outsourcing destination Asia Pacific.
In the Section 2, I will discuss in detail the doctoral study. The rationale for why I
chose the qualitative case study design and the importance of the role of the researcher,
the inclusion and exclusion criteria of the participants for the study, the population and
sampling, the data collection techniques and data analysis. A detailed discussion in each
of the above sections will explore pharmaceutical leaders’ procedural policies leading to
successful outsourced clinical trials. In Section 3, I will describe the application to
practice and to implement change. In addition, I will provide a detail description of (a)
overview of the study, (b) presentation of the findings, (c) application to professional
practice, (d) recommendations for action, (e) recommendation for the further research, (f)
reflections, and (g) study conclusions.
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Section 2: The Project
Section 1 of this doctoral study presented research information on various
pharmaceutical challenges such as regulatory laws, patent expiries, the high cost of
developing drugs in research, and development pushing pharmaceutical leaders to
outsource clinical trials to developing countries in an attempt to be more cost effective. In
Section 1, I explored the current problem that exists when clinical trials are being
outsourced to developing countries. In Section 2, I will provide a detailed description of
the research method and design of the study. Furthermore, Section 2 contains (a)
researcher role, (b) the participants for the study, (c) the research method and design, (d)
population sampling, (e) ethical research, (f) data collection and organization techniques,
(g) data analysis, and (h) the reliability and validity of the study.
Purpose Statement
The purpose of this qualitative case study was to explore strategies clinical quality
assurance managers use to avoid a breakdown in quality with outsourced clinical trials in
Asia-Pacific countries. The data collected from clinical quality assurance managers
provided information on why breaks occur or do not occur within the total quality
management system after agreed quality contracts to reduce the risk in clinical trials.
Participants came from the clinical research and development sector of one
pharmaceutical organization located in the Northeast region of the United States. The
information provided by clinical quality assurance managers may contribute to social
change through the creation of strategies to avoid quality breakdowns with outsourced
clinical trials.
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Role of the Researcher
My role as the researcher for this qualitative case study was to gain access to the
investigational research site and gain the trust of my research participants (Hancock &
Algozzine, 2011; Marshall & Rossman, 2014) to gather good data.. My role was to
isolate and define the qualitative categories and phenomenon. According to Fink (2000)
and Hancock and Algozzine, the researcher needs to understand the research being
studied. In order for me to understand the research, I answered the question of what in the
research is going to be studied, why it is going to be studied, and how it is going to be
studied. The answers to these questions will drive what will become the background in
the study analysis and reporting.
I have 15 years of experience as a global development quality manager both in
clinical trials and manufacturing sites. The study participants were quality assurance
colleagues; however, they were from different line functions within the clinical quality
assurance organization. Line functions within clinical quality assurance include but are
not limited to eClinical, outsourcing, audit, clinical, compliance, training, vendor, drug
regulatory, and pharmacovigilance. As a global quality manager, I am trained and
frequently certified on clinical trial ethics and human subjects’ rights. In addition, I
completed the National Institute of Health (NIH) web-based training course Protecting
Human Research Participants, exhibiting my knowledge of ethical behavior and the
research process (Appendix E). My role as a researcher was also to recognize my
personal bias and bias to the research. My role within the organization is quality
assurance manager. Because of my role, I mitigated the effects of my prejudice and bias
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to ensure impartiality to the research conclusions (Hancock & Algozzine, 2011). I used
methodological triangulation from different sources to increase the reliability of the data
(Barratt, Choi, & Li, 2011). The use of methodological triangulation minimized bias from
me as well as the participants. Furthermore, I used member checking of interview
transcripts to minimize bias and help identify data analysis themes and data results
(Onwuegbuzie, Leech, & Collins, 2010).
For this study, I was the data collection instrument. I used an interview protocol to
manage the available time of the interview session and focus on the 10 interview
questions. I took detailed notes during the individual semistructured interviews in an
appropriate private interview setting (Hancock & Algozzine, 2011). I transcribed the
interviews verbatim into a Word document, analyzed and coded the data, as well as,
verified and reported the data (Fink, 2000; Hancock & Algozzine, 2011). To ensure the
ethical and legal requirements of research were followed, I collected the participants’
signed informed consent forms prior to conducting the interviews (Hancock & Algozzine,
2011).
Participants
Suri (2011) noted the researcher choosing participants for semistructured
interviews must establish a sampling strategy conceptually aligned with the research
purpose, which adequately addresses the research design. The criteria of the research
participants included a minimum of 5 years of experience within the clinical quality
assurance organization. Only clinical quality assurance managers who had experience
with Asia Pacific outsourced clinical trials were included. Participants were at least 18
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years of age or up to 65 years of age to enter the study. The strategy to gain access to the
purposive sample of the 15 clinical quality assurance managers was from an invitation
via e-mail or through teleconference meeting invitations (Appendix A). I followed up
with a phone call or e-mail to answer any questions or concerns the participants may have
about the study. After participants gave confirmation to volunteer for the study, I sent an
informed consent form (Appendix B). Once I received the signed informed consent, I
asked participants if they would like to have a face-to-face interview, phone interview, or
e-mail questionnaire. The face-to-face interview was the ideal method; however, alternate
methods were used if participants were unable to make the face-to-face interviews.
Building a relationship with the participants helps the researcher gain access to the data
(Patton, 2005).
To establish a working relationship involving trust, open communication, and
positive interaction with the clinical quality assurance participants, I drew upon my
interpersonal skills. It was critical for me to build trust; be patient; be a thoughtful,
sensitive, empathetic listener; and be respectful of the participants (Marshall & Rossman,
2014). The positive work relationships created a safe and comfortable atmosphere for the
participants during the interview process. The data collected from clinical quality
assurance managers provided information on why quality breaks occur in outsourced
clinical trials in Asia Pacific after agreed quality contracts.
Research Method and Design
In this section, I expand upon the information presented in Section 1 on the
research method and design. I describe various research methods and designs while
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justifying why one particular research method and design was chosen. I justify why the
qualitative case study was the best-suited research method and design to answer my
research question: What strategies do clinical quality assurance managers use to avoid a
breakdown in quality with outsourced clinical trials in Asia-Pacific countries?
Research Method
There are three research methods a researcher chooses from: qualitative,
quantitative, and mixed methods. In a qualitative study, the researcher’s specific interest
is trying to uncover the meaning of the phenomenon of those involved (Merriam, 2014).
Marshall and Rossman (2014) and Merriam noted that qualitative studies are used for
descriptive or exploratory research that focuses on participants’ lived experiences and
settings. Bartkowiak (2012), Marshall and Rossman, Merriam , Patton (2005), and
Thomas and Magilvy (2011) agreed the key benefit of qualitative research is to
understand how people interpret their experiences through various research designs. To
understand the reasons why breaks occur or do not occur in quality management system
Asia-Pacific outsourced clinical trials, in-depth description from clinical quality
assurance managers was needed to understand the phenomenon. Merriam noted there are
four characteristics that identify qualitative research methodology: (a) the primary
instrument for data collection and data analysis is the researcher, (b) the product is
descriptive, (c) the focus is on meaning, process, and understanding, and (d) the process
is inductive. Maxwell (2012) emphasized that when a researcher possesses any of the
following five intellectual goals for the study, the best methodology is qualitative: (a)
generating new grounded theories, (b) identifying unanticipated phenomena and
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influences, (c) understanding the process by which actions and events take place, (d)
developing casual explanations, and (e) understanding the participant's perceptive.
Similarly, Hsuan and Mahnke (2011) recommended qualitative research for process
inquiries to seek understanding of how pharmaceutical managers manage the outsourcing
R&D and address gaps in the process. Kurkkio, Frishammar, and Lichtenthaler (2011)
noted that qualitative research is used to seek information on new process developments
when little if any information is given in prior studies. Hunt (2011) noted that if a
researcher uses the following five methods within his or her research, then the research is
qualitative: (a) seeks answers to questions, (b) collects evidence, (c) systematically uses a
predefined set of procedures to answer the question, (d) produces findings that were not
determined in advance, and (e) presents findings that are applicable beyond the
immediate boundaries of the study. Bernard (2013) suggested that a qualitative method
was appropriate to gain insight from pharmaceutical R&D leadership on how outsourcing
clinical trials to Asia Pacific was affecting the overall quality of the trials and how one
could improve quality business practices. The optimal way of collecting data was through
face-to-face semistructured interviews or telephone interviews that aligned with the
qualitative research method of collecting data and the researcher being the instrument to
collect data. The qualitative research method allowed for more flexibility, and interview
questions were open ended.
For quantitative research, there are specific research questions that are answered
by proposition tests or hypotheses being examined (Marshall & Rossman, 2014).
Merriam (2014) emphasized the focus of quantitative research is how much or how
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many. Bernard (2013), Johnson and Christensen (2008), and Oleinik (2011) noted the
goals of the investigation for the quantitative methodology are confirmation, description,
prediction, control, and hypothesis testing. Quantitative methodology was not appropriate
for this study because there were no numeric data being collected or hypotheses being
tested. To gain insight into quality trial processes from the R&D participants, open-ended
questions were needed; quantitative research relies on fixed response options.
Quantitative research does not provide flexibility because questions are closed and
participants’ responses do not influence how or which questions are asked next.
The final methodology is mixed methods, which is used when a researcher
collects both quantitative and qualitative data from either a series of studies or a single
study (Cameron, 2011; Mengshoel, 2012; Tashakkori & Teddlie, 2010). The mixed
methods approach helps the researcher determine whether an intervention works or why
it does not work, as well as how it delivers (Farquhar, Ewing, & Booth, 2011). According
to Farquhar et al., mixed-methods are particularly advantageous in research when the
process evaluation is challenging and most of the interventions are challenging. Cameron,
Farquhar et al., Onwuegbuzie et al. (2013), and Tashakkori and Teddlie noted that mixed
methods would not be appropriate for gaining insight into pharmaceutical leadership
knowledge of the clinical trial process for outsourcing clinical trials.
Research Design
Five primary research designs exist in qualitative research: phenomenological,
grounded theory, ethnographic, narrative, and case study. In order to explore the clinical
quality assurance managers’ knowledge of quality management system breakdowns in
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the outsourced clinical trial in Asia Pacific, I used a single case study. A single case study
was also preferred by previous researchers examining pharmaceutical R&D leadership’s
knowledge of management and barriers within the internal R&D departments to enhance
applications of the knowledge management team (Lilleoere & Hansen, 2011). Similarly,
Zhang, Pawar, Shah, and Mehta (2013) conducted a case study to investigate how to
assess outsourced work and manage outsourcing relationships in the pharmaceutical
industry. Jensen (2012) recommended case studies as the best approach for the offshore
outsourcing process to provide a detailed description of influential factors of the process.
According to Yin (2014), a case study is an empirical inquiry conducted to
investigate a contemporary phenomenon in depth and within a real-world context,
especially when the boundaries between the phenomenon and context may not be
apparent. The case study was the preferred method because the central research question
was what question, the focus of the study was a contemporary phenomenon, and I had no
control over behavioral events (Yin, 2014). In addition, Yin noted that multiple sources
of data in the case study allow a researcher to address a broader range of historical and
behavioral issues. In this single case study method, sources of data such as
documentation, archival records, responses to semistructured interviews, and direct
observations were used (Yin, 2014). I continued to interview the clinical quality
managers until data saturation was evident. Data became saturated when I determined the
reviewed data no longer had the new experience, perspective, and information.
Chikweche and Fletcher (2012) noted that data is statured when there is no new coding,
themes, and can replicate the results .The three classifications of case studies are
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descriptive, exploratory, and explanatory (Yin, 2014). In this case study, I chose
descriptive because the goal of the research was to provide a rich description of quality
management system breakdowns of clinical trials in developing Asia-Pacific countries
(Denzin & Lincoln, 2011; Yin, 2014).
I excluded the narrative research design because the focus of this study was not on
the lived experience of one or two individuals, and data collection was not through
collections of stories or experiences (Goulding, 2005). Additionally, the
phenomenological design was not chosen because the goal of the research did not have an
emphasis on the phenomenon explored or any individual or group who experienced the
common phenomenon (Merriam, 2014; Moustakas, 1994). Hays and Wood (2011)
suggested a grounded theory would not be appropriate for my study because the focus of
the research was not to develop a theory, and the focus of the research was not a
particular action that occurred over time. Finally, the ethnographic design was not
appropriate because my research aim was not to focus on a culture-sharing group
(Goulding, 2005).
Population and Sampling
The participants for this study were 15 clinical quality assurance managers
working in the R&D clinical sector in one pharmaceutical organization located in
Northeast region of United States of America. The 15 participants who met all the
eligibility criteria entered the study. The participant’s age was a minimum of 18 years to
65 years of age, working in or previous worked in clinical quality assurance organization
of the pharmaceutical organization. Participants will have at least 5 years of experience
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with clinical trials and have experience working with outsourcing organizations or
business process organizations.
The sampling method used for this qualitative case study is purposeful. Merriam
(2014), as well as, Suri (2011) noted a purposeful sample should be at least 15
participants to gain in-depth, rich data. Additionally, Boeije (2010) recommended a
sample size of at least 15 participants would be suitable or until data saturation. The
sample of the research participant occurs purposely to gain the knowledge of the varied
experience of the participant's knowledge of quality management system breaks for
outsourcing clinical trials. The research participants were clinical quality assurance
managers who are contributing to quality and vendor oversight of the clinical trials on a
daily basis. Part of their job description is to adhere to regulations and standard operating
processes, as well as, handling quality breakdowns in the system, process, and clinical
trials. Clinical quality assurance managers mitigate risks of the clinical trials, conduct risk
and gap assessments of the clinical trial processes, participate in sponsored or federal
inspections, and are the point of the contact for outsourced clinical trials in Asia Pacific
when there are issues, concerns, or questions. Clinical quality assurance participants have
the essential information needed for this research study.
Patton (2005) noted that power and logic of purposeful the sample come from
selecting information risk cases for study in-depth. The purposive sample approaches of
15 participants were face-to-face semistructured interviews with open-end research
question, which allowed the participants’ knowledge of outsourcing clinical trial process
phenomenon (Bartkowiak, 2012; Suri, 2011). Yin (2014) noted that conducting
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semistructured interviews will bring forth insight and help the focus stay targeted on the
study topic. The open-ended interview questions provided a guide conversation between
the participants and myself, as well as, allowed the interviewees to build on their ideas,
concepts, and thoughts. Furthermore, the semistructured interviews allowed me to follow
up with questions through member checking to expand on their experiences. The
interviews took place in the private setting environment such as a private and isolated
meeting room within the pharmaceutical organization.
Ethical Research
Ethical research requires qualitative researchers to show they are trustworthy,
reliable, and credible (Patton, 2002). I submitted the research study proposal and
informed consent to the Walden University's Institutional Review Broad (IRB) for review
and approval prior to collecting any data on participants. The informed consent provided
information to the research participants: (a) the nature of this case study; (b) inform him
or her of their rights that no harm, coercion, or deception will come to them in the study;
(c) protection of their privacy and confidentiality; (d) protect the vulnerable groups;
and(e) selecting participant equitably (Abramson & Abramson, 2011; Yin, 2014). Each of
the research participants received an informed consent (Appendix A) and given ample
time to read and determine if they may want to participate in the study. A participants’
signed informed consent was collected before entering the study. A copy of the signed
informed consent was given to the participant for their records. Furthermore, this initiated
the enrollment of the participants in the study.
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The study did not involve participants who are particularly vulnerable or unable to
give informed consent. To minimize risk to the human subjects, I utilized consistent
procedures, sound research design, and avoided unnecessary risks to subjects (FDA
Regulations, 2015). The risks to subjects were reasonable in relation to anticipated
benefits, if any, to subjects, and the importance of the knowledge that is expected to
result (FDA Regulations, 2015). The research participants voluntarily participated in the
study and could withdraw from the study at any time or choose not to answer an
interview question if they are uncomfortable to do so. The participant could withdraw by
contacting me via e-mail or telephone if they are no longer interested in participating in
the research study. The participants could withdraw from the study at any time. All data
collected from participants who have withdrawn are destroyed or deleted from the
database, and any written documents are destroyed. To protect the identity of the study
participants, I assigned a code CQA1-CQA15 to each participant. To protect the identity
of the pharmaceutical organization, I assigned a code name XYZ pharmaceutical
organization. In order to enter the study, the participants must be at least 18 to 65 years of
age, as well as, mentally stable (FDA Regulations, 2015). During the study, there were no
compensations, gifts, reimbursements, and free services for participation in this research
study (FDA Regulations, 2015).
In order to protect the rights of the participant’s data, it was maintained in safe,
secure locked storage and archived for 5 years. Participants’ personal information was
stored on my personal computer files and on a memory stick. Participants’ data were
protected by encrypted, and password protected computer files and labeled by the
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participants’ coded name. After 5 years, data will be destroyed through shredding of
documentation and deleting data from the computer files. I signed a confidentiality
agreement (located in Apendix D) due to the highly confidential information received
from the research participants..
Data Collection Instruments
In this single case study, I am the primary data collection instrument through faceto-face, or telephone semistructured interviews or e-mail interviews. Yin (2014) noted
one of the most key sources of case study evidence is the interview. Chenail (2011) and
Denzin and Lincoln (2011) recommended that in conducting qualitative research the
researcher is the key person who is obtaining the participant's data and, therefore, the
instrument. I conducted semistructured interviews to allow both myself and the
participants to have in-depth interviews through a conversation style and build a level of
comfort and familiarity to allow for a sustainable, meaningful interview (Barratt, 2012).
In addition, Chenail summarized that when a researcher facilitates a conversational style
that a context is created where the participants feel comfort and share rich data through
their lived experiences. Cook (2012) and Barratt, (2012) recommended that online
interviews provide participants more flexibility and time to answers questions Online
interviews also provided extra confidentiality of the sensitive topic that most participants
may not feel comfortable in a face-to-face environment (Markham, 2008). Gill, Stewart,
Treasure, and Chadwick (2008) were also in alignment that semistructured interviews
was the best approach because it explored the individual experiences, views, and beliefs
on specific matters such as the quality of the outsourcing clinical trial processes.
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Interviews were the most appropriate method of collecting data in a qualitative case study
because they provided a deeper understanding of the social phenomena and can be used
to collect detailed insights about the quality of the outsourced clinical trial processes from
the R&D participants (Barratt, 2012; Chenail, 2012; & Gill et al., 2008).
The processes, I followed for collecting data from the participants: (a) study
invitation and informed consent to the research participant Appendix C and Appendix A;
(b) research participant signed the informed consent to participate in the research study;
(c) both the research participant and me scheduled an appropriate time and date for the
interview; (d) conduct the interview in a confidential interview setting; (e) for research
participants who did not want a face-to-face interview, they completed online
questionnaire and returned to the researcher within a few days; and (f) follow up
meetings were also scheduled on any interview transcripts that need further clarification.
The semistructured interview consisted of 10 construct study specific sets of open-ended
questions located in Appendix B. The data collection instrument was critical in
identifying themes in data collection. Since, I am the data collection instrument all
participants’ data coded by experiences and perception from the interviews.
Yin (2014) recommended establishing quality tests in qualitative case study
research are reliability and validity. Bernard (2013) defined validity is the trustworthiness
and accuracy of the instrument. In this case study, I (a) reviewed interview questions to
ensure interview questions meet the aim of the research study, (b) the questions were
clear and concise for the research participant to understand, (c) prepare for the interview
sessions to provide for consistency of all R&D participants, and (d) utilize the pyramid of
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evidence from peer-reviewed research and expert opinion is the basis for ensuring
reliability and validity of the data collection instrument. In order to enhance data through
reliability, I transcribed my interview notes verbatim into a Word document. I utilized
NVivo 10 software to generate themes and patterns from the interview transcripts (Gill et
al., 2008). At the end of each interview session, I conducted a member check by emailing each research participant the interview transcript to ensure the information
transcribed correctly. In addition, follow up interviews questions were asked if interview
answers are unclear. Merriam (2014) and Bernard (2013) recommended researchers
organize data through themes, patterns, and concepts for descriptive data analysis coding.
According to Yin (2014), process check improves the instrument, questions, and
measures of the instrument. I conducted a process check after interviewing two research
participants to improve the interview questions or methods.
Data Collection Technique
The data collection techniques for this single case study were a face-to-face
semistructured interview, telephone interviews, or e-mail questionnaire; and
documentation from literature reviews, XYZ pharmaceutical organization’s quality
reports, and federal government reports. The advantages with documentation are stability,
unobtrusive, specific, and broad (Yin, 2014) and the advantages of interviews are it is
targeted and insightful (Gill et al., 2008; Yin, 2014; Merriam 2014). Yin noted one of the
most significant utilization of documentation is to corroborate and augment the evidence
from multiple sources. The semistructured interviews consisted of 10 opened ended
research questions to collect information from the research participants of the quality of
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clinical outsourced trial processes located in Appendix C. Merriam summarized the
importance for a researcher to conduct interviews is to obtain a kind of information
through a conversation with purpose (Patton, 2005). In addition, Barratt (2012); Chenail;
and Merriam noted that semistructured interviews provide flexibility of the research
questions, specific data required from all of the participants, interview guide consist of
mix of structure questions, and majority list of research questions for the interview are to
be explored. Face-to-face semistructured interviews are preferred, however due to the
multiple locations of the R&D clinical sites within the XYZ pharmaceutical organization
alternative method of telephone and e-mail questionnaire is given to allow for the
participation flexibility. Cook (2012) and Barratt (2012) recommended online interviews
provided participants more flexibility and time to answers questionnaire. It also provided
extra confidentiality of the sensitive topic that most participants may not feel comfortable
in a face-to-face environment (Markham, 2008). Even though there are strengths in
conducting interviews and collecting data from documentation there are also associated
disadvantages such as retrieve ability of documentation, documentation access, response
bias for interview questions, reflexivity, and participants uncomfortable to answer
questions on sensitive topics (Yin, 2014).
After the completion of the first two interviews, a process review check of
research questions and responses to ensure the aim of the research (Yin, 2014). After
interviews were transcribed, the text is downloaded to NVivo 10 software. Once the data
was transcribed verbatim, a member check occurred. The participants’ reviewed
transcripts for accuracy.
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Data Organization Technique
All data collected from interviews, informed consents, interview transcriptions,
and documentation are stored on my locked password protected the computer. In
addition, to avoid data from being lost or damaged, data was also stored on a password
protected memory stick. Merriam (2014) and Maxwell (2012) recommended for large
amount of data collection from field notes, documentation, and interview, the qualitative
researcher needs to find a structure to organize data. While Yin (2014) noted the case
study database should be orderly where the data is retrievable. Data collected from
documentation and interviews labeled and filed in the main study folder quality data file
and the subfolder were labeled with participant's coded name clinical quality assurance
participant (CQA) 1-15 where all corresponding informed consents, transcripts, and hand
written notes were stored and filed. All raw data collected from this study in a locked
password protective storage container for five years. After 5 years, I will destroy data by
deleting all data from memory disk and the password protective laptop.
Data Analysis
Data analysis involves immersion of the data, organizing the data, generating
themes and patterns, coding the data, integrating and summarizing the information that
the researcher has read and observed, thus providing meaning to the data (Marshall &
Rossman, 2014). What strategies do clinical quality assurance managers use to avoid a
breakdown in quality with outsourced clinical trials in Asia-Pacific countries?
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1. How do clinical quality assurance managers regulate the clinical quality
management systems and adapt to changes when trials are outsourced to
Asia Pacific?
2. How do clinical quality assurance managers ensure that clinical trial
vendors adapt to the changes in the environment and process negative
feedback?
3. What actions are taken by clinical quality assurance managers to ensure
outsourced clinical trial vendors are following the agreed contracts?
4. What strategies do clinical quality assurance managers employ to ensure
compliance from an outsourced clinical trial vendor after an agreed quality
contract?
5. What are some risks and benefits associated with clinical trials when
outsourced to Asia Pacific?
6. How do clinical quality assurance managers build successful relationships
with clinical trial vendors and sustain those relationships with an everchanging outsourcing business model?
7. How do clinical quality assurance managers ensure standard methods of
communication of newly released standard operating processes,
regulations, systems, and tools to outsourced clinical trial vendors?
8. In a 1-year time frame, how often do clinical quality assurance managers
and outsourcing vendors reassess quality agreements, contracts, processes,
and potential gaps?
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9. What strategies have/have not worked with outsourcing clinical trials to
ensure the highest quality of the clinical trial?
10. Is there any additional information you would like add that I may not have
addressed by the interview questions?
Denzin and Lincoln (2011) noted the use of triangulation in qualitative research
secures in-depth understanding of the central research question. In addition, Marshall and
Rossman (2014); Oleinik (2011) and Yin (2014) asserted that methodological
triangulation strengthens the quality of the case study because multiple sources provide
multiple measures of the same phenomenon. The use of methodological triangulations
from various sources such as documentation from XYZ pharmaceutical organizations’
quality reports and federal agencies reports and interviews allowed me to form an
understanding of the quality management system breaks (Jensen, 2012). Once the data
was collected from the interviews, I transcribed interview notes verbatim to a Word
documents; the NVivo 10 software assisted with identifying, sorting, and coding of
themes and pattern analysis. Yin supported computer-assisted tools such as NVivo
software because it is a tool to help guide researchers to categorize and code large
amounts of data. Denzin and Lincoln noted NVivo software assists researcher in data
coding, content analysis, and helps to identify themes and patterns. Yin noted the
conceptual framework assists in data analysis in a case study, which provided structure to
analyze the research question. One of the strengths of using the case study is the diverse
data sources through triangulation, which provided an accurate understanding of the
phenomena. Hence, the use of reflexivity and triangulation improved my understanding
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of the complex nature of the phenomenon, as well as, allowing me to explore the
subjective experiences of the quality assurance managers.
The conceptual framework for this study developed from von Bertalanffy’s
(1968) general systems theory. For outsourced clinical trials to have the utmost quality,
the clinical trials must adhere to standard operating processes, quality management
system, and federal and local regulations. In order to maintain the highest quality
standards, the pharmaceutical organization must have a robust quality management
system. Laszlo and Kippner (1998) noted the concept of the general systems theory is it
integrates with complex component relationships and identifies boundary maintaining
processes or entities. Senge et al. (2011) noted leaders are seeking to understand how to
deal with information and how to utilize it for sustainable innovation. In order for the
pharmaceutical organization to enhance the outsourcing quality environment,
organizations’ leaders should integrate compliance or beyond compliance to their
business environment.
Reliability and Validity
Reliability
The main concern in a qualitative research study is to produce reliable and valid
results (Merriam, 2014). Yin (2014) defined reliability as demonstrating data collection
procedures repeats with same results. Wahyuni (2012) compared reliability to the
dependability of the qualitative research through operational processes. In order for
another researcher, to produce reliable and valid results they must follow the same
operational procedures to produce the same finding and conclusions. To ensure
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dependability, prior to the interview I reviewed interview questions and prepared for the
interview to ensure reliability. Merriam (2014) noted in a qualitative research study, a
human instrument can make the study more reliable by training and practicing. Seidman
(2012) noted recordings enhance reliability by preserving the participant words, and it
becomes the source data, and researcher should ensure the quality checks are made to the
recorded prior to interviews. A list of follow-up questions is created from interview
transcripts to allow further clarity on participants’ responses. To enhance the interview
process, I conducted a transcript review check after the first three interviews to verify
interview accuracy (Yin, 2014). Therefore, to ensure reliability for the study, I utilized
member checking for (a)notes and data, (b) audit interview questions for consistency, (c)
review interview transcripts for any errors, (d) practice my interview skills, and (e)
document all data collection procedures. In addition, I demonstrated the credibility of this
single case study design by achieving data saturation through credible processes
(Houghton, Casey, Shaw, & Murphy, 2013).
Validity
In this qualitative single case study, I used both internal and external validity tests
to establish quality in case study research (Yin, 2014). For internal validity is when the
researcher interpretation is correct when there is no direct observation (Yin, 2014). In the
external validity, domains are established in order for the results to generalize (Yin,
2014). Maxwell (2012) described validity as the creditability of the description,
conclusion, interpretation, and explanation. Merriam (2014) noted achieving credibility in
qualitative research studies can be achieved through the personal experience phenomenon
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to obtain thick, rich, descriptions and in-depth participant interviews to receive rich data.
To ensure internal validity/credibility, I transcribed semistructured interviews verbatim
and reviewed transcripts for any errors, and used follow-up questions for clarity and
member checking. In addition, all interview transcripts will be e-mailed to the research
participants for review to ensure data accuracy. I used the NVivo 10 software for theme
and pattern analysis. In addition, member checking ensured transcript review; peer
debriefings were conducted after to discuss gathered data and used methodological
triangulation by collecting data from multiple sources (Yin, 2014). Marshall and
Rossman (2014) recommended addressing any concerns with the validity the researcher
constructs to capture through credibility, transferability, dependability, and
confirmability.
To establish external validity for this qualitative single case study, I used the
methodological triangulation method (Yin, 2014). The data collected from interview
transcripts and documentation such as field notes, government reports, and xyz
pharmaceutical organization's quality reports will provide validity. Maxwell (2012) noted
triangulation can reduce the risks of bias and strengthen the validity. Furthermore, Yin
noted the researchers who utilize using multiple sources of evidence in case studies are
rated highly in terms of overall quality. Marshall and Rossman (2014) also recommended
triangulation and member check as the strategy for internal validity in a qualitative
research study. While Trotter (2012) noted in qualitative research creditability equates to
internal validity. To establish dependability, credibility, and transferability, I triangulated
data from documents and interviews; use member checking as participants review their
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interview transcripts and develop rich, thick descriptive themes and pattern (Harper &
Cole, 2012) through NVivo 10 software. Transferability of this study is by referencing
the research sources to allow future researchers, as well as, the readers to determine
whether the information transfers to enhance clinical business practices
(Nawakitphaitoon, 2014). Therefore, to improve the credibility or trustworthiness of the
data and quality, I used semistructured interviews, member checking, and researchers’
notes.
Transition and Summary
The purpose of this qualitative case study was to explore quality breaks when
clinical trials are outsourced in Asia Pacific region. In Section 2, I described the (a)
researcher role, (b) the participants for the study, (c) the research method and design, (d)
population sampling, (e) ethical research, (f) data collection and organization techniques,
(g) data analysis, and (h) the reliability and validity of the study. In Section 3, I will
describe the application to practice and implication for change. I will provide a detail
description of the following (a) overview of the study, (b) presentation of the findings, (c)
application to professional practice, (d) the implications for social change, (e)
recommendations for action, (f) recommendation for further research, (g) reflections, and
(h) study conclusions.

69
Section 3: Application to Professional Practice and Implications for Change
Introduction
The purpose of this qualitative case study was to explore strategies clinical quality
assurance managers use to avoid a breakdown in quality with outsourced clinical trials in
Asia-Pacific countries. In this study, I conducted semistructured interviews with 15
clinical quality assurance senior managers to explore strategies on how to avoid quality
system breakdowns with outsourced clinical trials. The three emergent themes that I
identified from the participants’ interviews were the following (a) quality vendor
management of outsourced vendors, (b) building quality in outsourced clinical trials, and
(c) quality management system. All of the research participants reported that to improve
quality and avoid quality breaks with a clinical trial, managers should maintain a robust
quality management system and closely monitor the outsourced vendor. The research
participants also reported that a close relationship between vendor and client
characterized by trust and communication correlated to outsourcing success. The final
strategy, which the majority of the research participants reported to be the principle
method for research and development to maintain and improve drugs and service quality,
was implementation of a quality management system. Exploration of the clinical quality
assurance outsourcing strategies may provide process improvements to the outsourcing
clinical trial business model, higher quality submissions to regulatory agencies, and a
decrease in quality improvement costs.
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Presentation of the Findings
The overarching research question for this study was the following: What strategies
do clinical quality assurance managers use to avoid quality breakdowns with the
outsourced clinical trials in Asia-Pacific countries ? To answer the overarching research
question the following open-ended semistructured interview questions asked were:
1.

How do clinical quality assurance managers regulate the clinical quality
management systems and adapt to changes when trials are outsourced to
Asia Pacific?

2.

How do clinical quality assurance managers ensure that clinical trial
vendors adapt to the changes in the environment and process negative
feedback?

3.

What actions are taken by clinical quality assurance managers to ensure
outsourced clinical trial vendors are following the agreed contracts?

4.

What strategies do clinical quality assurance managers employ to ensure
compliance from an outsourced clinical trial vendor after an agreed
quality contract?

5.

What are some risks and benefits associated with clinical trials when
outsourced to Asia Pacific?

6.

How do clinical quality assurance managers build successful relationships
with clinical trial vendors and sustain those relationships with an everchanging outsourcing business model?
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7.

How do clinical quality assurance managers ensure standard methods of
communication of newly released standard operating processes,
regulations, systems, and tools to outsourced clinical trial vendors?

8.

In a 1-year time frame, how often do clinical quality assurance managers
and outsourcing vendors reassess quality agreements, contracts,
processes, and potential gaps?

9.

What strategies have/have not worked with outsourcing clinical trials to
ensure the highest quality of the clinical trial?

10.

Is there any additional information you would like add that I may not
have addressed by the interview questions?

To explore clinical quality assurance managers’ strategies to avoid quality breaks
with outsourced clinical trials, a qualitative case study was the optimal approach. Due to
the XYZ pharmaceutical organization’s policy on audio recording, the face-to-face
interviews were not audio recorded. However, the face-to-face interviews were
transcribed from notes taken during the interview into Word documents and sent to the
research participants for transcript review. I used the NVivo 10 software to assist with the
coding and analysis of data collected from interviews and questionnaires to identify
potential themes. I identified three emergent themes: (a) quality vendor management, (b)
building quality in outsourced clinical trials, and (c) successful management and
implementation of quality management systems.
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Theme 1: Quality Vendor Management
The clinical quality assurance senior managers reported that the strategies to avoid
quality breaks with outsourced clinical trials were to manage quality oversight of the
outsourced vendor. To improve quality and avoid quality breaks with a clinical trial,
vendor should maintain a robust quality management system and closely monitor the
outsourced vendor. Kennedy, Nordrum, Edwards, Caselli, and Berry (2015) noted the
following ways to improve vendor quality: (a) build quality culture, (b) provide risk
management tools and detectors, (c) monitor progress through metrics, (d) communicate
service standards, and (e) provide education and training. Similarly, Medina and
Richmond (2015) noted that there were increased numbers of industry-wide quality
breaches and consequential drug shortages, which fueled FDA interest to improve the
quality of pharmaceutical organizations. One method for quality improvement involved
quality metrics by FDA inspectional resources, use of the risk-based paradigms, and
communication of the quality status of various companies to other stakeholders. Medina
and Richmond found the most valued metrics within the pharmaceutical organization
were FDA metrics, such as warning letters and observations. Medina and Richmond
stated that the survey respondents were hesitant to share information on metrics for key
process indicators that would signal quality problems sooner. Medina and Richmond
agreed with the FDA Request for Quality Metrics (2015) that the pharmaceutical
organization is the most important stakeholder for the development and rating of quality
metrics. Both Medina and Richmond and the FDA Request for Quality Metrics argued
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that senior level management’s commitment to quality was a key factor in evaluating the
overall quality culture within the pharmaceutical organization.
The results of the research study confirmed findings from similar studies (Kennedy et
al., 2015; Medina & Richmond, 2015; Temkar, 2015) that quality oversight and
management were critical to avoiding quality breaks with outsourced clinical trials.
Examples of research participants’ (coded CQA1-CQA15) responses included were the
following:


“Vendors go through a qualification process, are periodically audited, and are
monitored on an ongoing basis. Have regular scheduled QA meetings with
vendors to review/discuss the status of issues and projects.” (CQA7)



“Clinical quality assurance has country specific quality assurance associates
as checkpoints in Asia Pacific to monitor and oversee activities in outsourced
clinical trial vendors.” (CQA15)



“Per procedure, all clinical vendors require some level of oversight by the
pharmaceutical organization. Larger strategic vendors have operational
oversight and executive level steering committees to provide high-level
oversight and feedback. At an operational level, Key Performance Indicators
are used by study teams to monitor vendor performance and act as an
indicator that corrective actions must be taken. Key Performance Indicators
have been standardized for all high risk clinical services.” (CQA8).
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“A clinical quality assurance representative is assigned to the study based on
function the outsourced vendor would provide. This ensures a more focused
and consistent approach to managing quality breaks.” (CQA4)



“CQA holds quarterly contract/statement of work reviews with our vendor as
well as an annual governance meeting” (CQA5).



“A checklist based on the activities delegated to the vendor should be created
and used as a tool for the continuous oversight of the vendor. This can be
carried out by on site audits, review of resulting data or questionnaires to the
vendor that request documented evidence of fulfilment of the contract
requirements.” (CQA6).



“Frequent audits, particularly close audits of CVs and training records are
certainly important to ensure the appropriate personnel are being assigned as
per the contract—which should specify clear and detailed requirements. In
addition, a sound signals detection program is needed that incorporates data
management oversight at the sponsor as well as automated monitoring of the
data and documentation on an ongoing basis.” (CQA1)



“The only way to actually determine if vendors are following conditions in the
contracts is to audit them and hold them accountable to a Corrective Action
plan.” (CQA9).



“The strategies we use to ensure quality at outsourced clinical trials is using
quality oversight such as audit activities, measuring key risk and compliance
indicators.” (CQA3)
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This is a very delicate aspect, and needs to be handled as such. Stability in
how the vendor relationship is managed is essential, particularly during the
post-qualification trial execution phase, where robust vendor oversight and
close collaboration between sponsor and CRO are the key items to look at.”
(CQA11)



The qualification of clinical vendors and outsourcing of clinical trial activities
is performed via an approved XYZ pharmaceuticals standard process,
irrespective of the region where the services will be performed. This process
has been designed to take into account the risks associated with the service
being outsourced (primarily looking at risks to patient safety and data integrity
so that providers of similar services are assessed via process and level of
scrutiny).” (CQA8)

Research participants reported that vendor quality management of the outsourced
clinical vendor was essential to avoid any quality breaks. To establish quality oversight to
outsourced vendors, clear metrics should be determined and communicated to vendors to
ensure continuous quality. Clinical quality assurance senior managers should work with
specific clinical quality assurance groups and vendor operational excellence teams to
assess vendor and quality vendor contract agreements. The majority of the research
participants agreed that auditing vendors and implementing corrective and preventative
action plans enhances vendor accountability. Furthermore, the majority of the research
participants noted that the creation of a quality governance board was a key success
factor in vendor quality management. The quality governance board assisted both the
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clinical quality assurance managers and outsourced vendors to discuss quality issues,
audits, corrective and preventative actions, and current challenges. The board also
provided a platform to escalate potential risk and quality issues.
The FDA Warning Letters (2015) noted that the even though the clinical trials are
outsourced to vendors, the ultimate responsibility and accountability for the clinical trials
is with the pharmaceutical organization. The expectation of the FDA is pharmaceutical
organizations perform vendor quality management (FDA Warning Letters, 2015). Recent
FDA warning letters issued to the pharmaceutical organizations were due to lack of
vendor oversight of the contract research organizations (FDA Warning Letters, 2015).
Research participants supported implementing the vendor quality management program
to avoid quality breaks with outsourced clinical trials not only in Asia Pacific but in all
geographical regions of outsourced clinical trials.
Theme 2 Building Quality in Outsourcing Clinical Trials
Awareness of risks and benefits. The increased growth in outsourcing,
specifically with clinical trials, was triggered by pharmaceutical organizations’ effort to
reduce cost and focus on strategic plans (Abdul-Halim, Ee, Ramayah, & Ahmad, 2014).
The driving factor for many pharmaceutical organizations to outsource clinical trials and
clinical line functions was to reduce drug development cost and patient recruitment. The
outsourcing of various clinical line functions within R&D to CRO or BPO has been an
increasing trend (Huysmans et al., 2014) among pharmaceutical organizations to achieve
faster regulatory approval timelines. However, the majorities of the outsourcing projects
have been prone to failure (Huysmans et al., 2014) and have ultimately increased costs
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for pharmaceutical organizations to repair the damage. When any functionality of clinical
trial is outsourced, there are risks and benefits. The ultimate key question is do the
benefits outweigh the risks? If so, how can pharmaceutical organizations ensure high
quality and success with the outsourcing? The majority of the research participants
reported that there is far more risk than benefits when outsourcing to Asia Pacific. The
following are examples of the research participants’ responses:
•

“In the past, we have seen that some risks include lack of clinical trial
support experience at the vendor and extremely high vendor personnel
turnover. This can be disruptive to the management of the trial.” (CQA8)

•

“One risk to outsourcing to Asia Pacific is high turnover rate with Data
Management and Information Technology associates which leaves no
consistency and information lost and having to retrain new associated to
projects” (CQA14)

•

“Language barriers, time zone differences, lack of understanding clinical
protocols and clinical processes.” (CQA2)

•

“Risks are: cost savings are not as great as expected, underestimation of
the effort needed for ongoing quality/compliance, vendors lack experience
and high turnover of associates at vendors, weak with soft skills.” (CQA7)

•

“Risks may include a general language barrier, where the written and
spoken language in Asia Pacific are dramatically different that the EU and
US. In addition, local customs and regulations are solely managed by the
CPO. If the CPO is not well staffed, trained, or otherwise equipped, they
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may work in a vacuum and can miss important coordination with Global
partners.” (CQA10)
•

“Such relationships are particularly vulnerable to distance, time
differences and assurance of adequate training in regulations and guidance.
Potential delays in communication or vendor may need immediate
assistance with an emergent situation during hours when US counterparts
are typically unavailable.”(CQA5)

Research respondents had similar perceptive on risks, as well as, benefits. The two
major benefits that majority of the research participants discussed was cost benefits and
participant pool population for targeted diseases in the Asia Pacific region. Examples
such as:
•

“Cost savings are meant to be the primary benefit.” (CQA1)

•

“Benefits clearly include adequate penetration and enhanced
understanding of local markets and related challenges, as well as favorable
costing.” (CQA11)

•

“In my experience, one of the benefits of clinical trials outsourced to Asia
is cost, i.e. lower cost than the rest of the world. There is a large pool of
skilled resource. (CQA4)

Research participants’ responses on the benefits and risks associated with outsourced
clinical trials confirmed with current, as well as, past literature reviews (Abdul-Halim et
al., 2014; Huysmans et al., 2014; Mariani et al., 2014) on the risks and benefits for
outsourcing clinical trials. Research participants concurred having a quality risk
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management system and tools in place for data signal detection helped to determine what
clinical trials and clinical trial site were at higher risk.
Stronger vendor-client relationship. The majority of the research participants
reported that building better vendor-client relationships may enhance quality services by
minimizing quality risks with clinical trials. St. John, Guynes, and Vedder (2014)
conducted a study on the complexity of the IT vendor-client relationship, examined social
exchange factors difficult to address in vendor contract agreements, and the success
factor for vendor-client relationships. Their participants stated that a close relationship
between vendor and client characterized by trust and communication correlated to
outsourcing success (St. John et al., 2014). Similarly, a case study conducted by Moe,
Šmite, Hanssen, and Barney (2014) reported that companies had challenges with poor
communication, high turnover employee rate, domain knowledge, a lack of commitment
of external developers, as well as, cultural challenges. The termination of all four medium
sized outsourcing companies resulted because of low quality services. Research
participants’ responses were consistent with literature reviews (Moe et al., 2014;
Schwarz, 2014; St. John et al., 2014 & Qui & Chan, 2015), which reflected in their
response to build better vendor-client relationships:
•

“Good communication, clear escalation paths, and continuous involvement
QA can use their broad experience to provide advice about the planned
clinical trial procedures. They can give an independent viewpoint,
uninfluenced by other project concerns or pressures.” (CQA6)
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•

“Regular, transparent communication and modeling integrity in vendor
relationships encourages the flexibility and rapid response necessary to
meet/exceed quality standards and adjust when needed.” (CQA5)

•

“The clinical quality assurance also tracks trends on quality breaks and
discusses with the vendors where the same type of quality break occurs
more frequently than normal.” (CQA4)

Similarly, St. John, Guynes, and Vedder (2014) noted lack of communication
between client and vendor leads to lack trust, which leads to relationship failure. Time is
a key element on why the vendor-client relationship fails. The failure of the relationship
contributed to individuals who are too busy, separated by distance, time zones, and
language barriers. A common recommendation to build successful vendor-client
relationship is to communicate at least 10 minutes per day (St. John et al., 2014). Some
research participants felt vendor-client relationship could use improvement so clinical
quality assurance could be more proactive instead of reactive:
•

“Setting up of regular meetings with the vendor and being pro-active.
Unfortunately, I don’t believe we do this very well and with all that we
have in place, we are still in a reactive mode.”(CQA9).

•

“Unfortunately there is still lack of communication between various
outsourcing vendors, IT, and the clinical line functions. It seems when
quality breaks occurs that is when all parties come together to discuss in
the reactive mode.” (CQA13)
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The majority of the research participants’ responses aligned with Qi and Chau (2015)
stating the keys to building a successful vendor-client relationship are communication
and trust. Both literature reviews and research participants’ responses concluded that
having, maintaining, and building vendor-client relationships contribute to better quality
services and decrease quality breaks.
Theme 3: Successful Management and Implementation of QMS
The majority of the research participants’ felt that the principle method for research
and development to maintain and improve drugs and service quality is through successful
management and implementation of a quality management system. All of the research
participants’ felt implementing and maintaining the quality management system provided
document controls, controlled systems, standard operating processes, regulatory
requirements, and training provided better quality services. The following are ways that
clinical quality assurance managers regulate quality management systems, so it protects
and adapt to changes when clinical trials are outsourced to Asia Pacific:
•

“Ensure SOPs and other documents are in place and involved personnel
are appropriately trained. Ensure compliance is being monitored.”
(CQA12)

•

“Ensure that internal guidance is aligned with local/regional health
authorities and to ensure the outsourcing partners are trained and evaluated
for compliance on a regular basis.” (CQA5)

•

“Clinical QA needs to actively monitor activities performed by the
business, as well as performing their own reviews of SOPs at the vendor
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and requiring corrective action for deficiencies found. SOPs in Asia
Pacific need to be highly detailed, much more so that QA is accustomed to
seeing and requiring.” (CQA1)
•

“We have quality risk management tools and systems that give provide us
signal detection on the possible risks that exist at clinical sites to help
determine what sites may need to be audited.” (CQA15)

In addition, research participants agreed that the way to ensure the quality
management system adapt to changes in its environment, process negative feedback, and
produce stable equilibrium is by setting up quality management standards, such as ISO
9000. Many of the research participants agreed that the key critical success factors of
implementation of QMS are communication from R&D senior management and R&D
colleagues who understand the importance of it. However, one research participant
responded that negative feedback process could be challenging and focus should be more
process oriented than personnel.
•

“Negative feedback is particularly challenging culturally. I think keeping
the focus as much as possible on procedures rather than on personnel can
be helpful, but it is very important to work on developing an attitude of
quality vigilance and self-reporting on the part of the local personnel and
management.”(CQA1)

I noted the results of the study tied into existing literature, which showed that for an
organization to increase performance and quality services a QMS must be successfully
implemented. (Li, TU, & Lui, 2015; Kaziliūnas, 2010; Zelnik, Maletič, & Gomišček,
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2012). Kaziliūnas (2010) also noted that a quality management system based on
international standards, such as ISO 9000, may enhance quality performance and
services. Similarly, Zelnik et al. (2012) discussed that the organization’s senior leaders
need to motivate and understand the ISO 9000 standards, as well as, commitment to
successfully implement a QMS. One reason QMS is not implemented successfully is the
lack of involvement from both senior management and all employees (Zelnik, et al.,
2012). Both literature (Calabrese & Corbò, 2014; Kaziliūnas, 2010; Li et al., 2014) and
research participants’ responses aligned on how to successfully implement and manage a
QMS to produce higher quality product and services.
The results of the research study aligned with the study’s conceptual framework of
the general systems theory. According to the general systems theory, environmental
influences and time causes the whole system, as well as, its subsystem to be out of
balance and less maintained and controlled (Calabrese & Corbo, 2014; Kaziliūnas, 2010;
Stacey, 2011). Pharmaceutical managers used system thinking as a way to resolve
complex problems and designs. Leaders utilizing system thinking seemed to be at an
advantage for managing complex situations and uncertainty where there is no simple
situation. I noted the results of the research study confirmed with the existing literature
on effective business practice. Schmiedel, vom Brocke, and Recker (2015) noted that
organization’s culture plays a key role in the success or failure of a business practice to
be effective. In many organizations to measure if a business process is effective or not,
heavily relies on the organizational culture of self-reporting to report gaps or deviations
within the process. Research participants’ responses concurred with the literature that for
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a process to be effective there needs to be self-awareness and self-reporting culture to
address quality issues or gaps in the process. Many researcher participants’ felt the need
for clear communications of the new processes, training, audit findings and
standardizations across various business line functions would improve compliance.
Applications to Professional Practice
The purpose of this qualitative case study was to explore what strategies some
clinical quality assurance managers use to avoid breakdowns in quality with outsourced
clinical trials in Asia-Pacific countries. I identified three emergent themes to avoid
quality system breaks in outsourced clinical trials. The results of the study revealed that
strong vendor-client relationships, vendor quality management, and a successfully
implemented and managed QMS were key success factors to maintain and sustain highquality in outsourced clinical trials business practices. The majority of the research
participants’ felt that building strong vendor-client relationships with key business line
functions, outsourcing clinical vendors and quality assurance managers were essential to
building trust. The research participants’ felt that attending quality review board meetings
and governance steering committees to discuss ongoing challenges, metrics, risks,
processes, and having an open and clear communication on a regular basis assisted in
building effective quality processes. Qi and Chau (2015) study results aligned with
research participants’ responses that the leading success factors on the outsourcing
relationship in China were the successful formation of vendor-client relationship through
communication, quality, and trust. Wong, Tseng, and Tan (2014) noted to boost

85
organizations’ performance they need to configure business processes and a quality
culture model for the team performance to improve continuously.
The research participants stated senior management and employees need to
commit to the QMS to produce high-quality product and services. Zelnik et al. (2012)
also agreed that organization’s senior management should have motivation and
understanding of the ISO 9000 standards, as well as, a commitment to quality to
implement a QMS. Pharmaceutical organizations utilized quality management systems to
improve the quality of product and process to achieve continuous customer satisfaction
(Khanna, Sharma, & Laroiya, 2011).
Implementation of quality remains an important issue for global organizations,
which are continuously trying to improve their competitiveness (Khanna et al., 2011;
Johnson & Gupta, 2013). To gain global competitive advantage and to avoid quality
system breaks in outsourcing clinical trials, pharmaceutical business leaders can
incorporate these strategies to build quality within their organization. Also, the research
data provides insight to the leaders how to improve vendor-client relationships to build a
better relationship with internal resources and outsourcing vendor resources (Mendivil,
2012).
Implications for Social Change
The results of this study might bring about social change by improving strategies
for various organizations’ senior leaders to improve business relationships and producing
high-quality products to the customer. Senior leaders may want to use this information
for positive social change by creating quality culture awareness and commitment at all
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levels of management from both the vendor and organization. The quality culture
commitment from senior leaders may enhance the self-reporting culture; provide
empowerment and accountability amongst employees.
The data from this study may also assist communities economically by creating
quality assurance job opportunities globally to monitor the quality of products and
services. The quality improvements with outsourced clinical trials may produce a better,
more effective, safer drug to society. The quality improvements made within the clinical
trial processes may provide better knowledge of the quality of the drug, as well as, drug
side effects, which will enhance drug’s side effects reporting to federal agencies.
Furthermore, the data from the study may improve individuals’ knowledge of the quality
of the drug and change their behavior by self-reporting their drug side-effects back to the
organization to improve drug labeling. Ultimately, enhancing drug label information may
assist physicians to dose patients accordingly and to inform better the patients of known
side-effects.
Recommendations for Action
Pharmaceutical business leaders need to secure funding for quality commitments
and programs for clinical quality assurance managers to ensure proper quality oversight
to the outsourced clinical vendor. Such funding should cover frequent travel to build
vendor relationships, conduct audits, and provide training to enhance quality with
vendors. The clinical quality assurance managers, as well as R&D senior leaders, need to
communicate their quality commitments throughout the organization and implement a
sustainable quality plan.
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Kennedy et al. (2015) noted the ways to improve vendor quality were the
following: (a) build quality culture, (b) provide risk management tools and detectors, (c)
monitor progress through metrics, (d) communicate service standards, and (e) provide
education and training. Senior leaders should be aware and plan for offshoring BPO’s
cultural risk factors that often occur with client and vendor relationships (Holbrook,
2011; Mosher & Mainquist, 2011) to avoid future quality problems. Culture plays a
significant role when dealing with offshoring vendors. Communications, management
style, understanding each other culture, gender issues, quality management, and team
harmony are at risk if client and vendor have a serious communication break (Holbrook,
2011). Both Medina and Richmond and the FDA Requst for Quality Metrics (2015)
argued that senior level management’s commitment to quality was a key factor in
evaluating the overall quality culture within the pharmaceutical organization.
The study results would be the most beneficial for the R&D senior leaders. The
strategies identified from this study could provide R&D senior leaders with approaches to
avoid a breakdown in quality with outsourced clinical trials. Prior to this research, there
was limited information on how to avoid quality system breaks in outsourced clinical
trials. For the study results to reach a wider audience, the results should be disseminated
through business journals and scholarly literature. The results of this study may assist
pharmaceutical organization leaders gain insights on how to improve their outsourcing
models, vendor quality management, vendor-client relationships, and quality
management systems.
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Recommendations for Further Research
My recommendations for future research and improvements in business practices
are to duplicate this study from different global regions and different sample populations.
The clinical quality assurance managers have a robust quality background and training to
analyze risk and detect quality issues within clinical trials. The reason, I would
recommend another sample population, such as clinical trial managers is to gain insight
on the ongoing quality breaks seen in outsourced clinical trials. A different sample
population will bring further insights to pharmaceutical senior leaders to enhance quality
strategies and practices. My final recommendation is to study the practices of clinical
outsourced vendors from various geographic regions. The information from such studies
may provide insight and strategies to enhance quality business practices.
In research studies, there are limitations or weaknesses, and this study is no
exception. Two limitations of this research study were that I only explored one
multinational pharmaceutical organization and did not explore medium nor small size
pharmaceutical organizations. I recommend other researchers to explore numerous and
various sized pharmaceutical organizations to gain further strategies to avoid quality
system breaks. Duplication of this study from different global regions and from a small to
medium size pharmaceutical organizations may determine if clinical quality assurance
managers’ strategies are different or similar to this study. Another limitation to this study
was only including pharmaceutical organization and not CROs, BPOs, and biotech
organizations. My final research recommendation is to explore strategies that senior
leaders of outsourcing vendors utilize to avoid quality breaks. Exploring the strategies of
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outsourcing vendor management’s leaders may assist R&D pharmaceutical leaders to
enhance quality business practices and outsourcing models.

Reflections
This study was a success in exploring what strategies some clinical quality
assurance managers use to avoid a breakdown in quality with outsourced clinical trials in
Asia-Pacific countries. As a clinical quality assurance manager within the organization
from one sector of the overall development quality assurance organization, it was not
clear to me why quality breaks occur to outsourced Asia-Pacific clinical trials. I needed
additional clarity on why some pharmaceutical organizations seem more successful than
others. Over the last 10 years, an increasing trend for pharmaceutical organizations to
outsource clinical trials and clinical line functions to Asia Pacific. Asia-Pacific countries
are the most sought out destination for clinical trials, which raised interest in the quality
of outsourced clinical trials. My curiosity grew over the years; however, there was very
little research on quality aspect clinical trials and ways to improve outsourced clinical
trials to avoid quality breaks. The information of this study showed me that even though
various clinical quality assurance managers, from various concentrations of the clinical
trials, participated in the study, they all agreed on the strategies to avoid quality breaks in
outsourced clinical trials. While a few research participants were business colleagues and
my career is within the clinical quality assurance arena, I utilized reflexivity to check for
sources of personal bias. I used the methodological triangulation to ensure validity within
the research study. The data collected from interview transcripts and documentation such
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as field notes, government reports, literature reviews, and the XYZ pharmaceutical
organization’s quality report provided validity. I ensured study reliability by member
checking to verify the accuracy of my interpretations.
Summary and Study Conclusions
The high cost of conducting clinical trials forces the pharmaceutical leaders to
outsource clinical trials to developing countries. The outsourced clinical trial model saves
money, time, provides faster drug approval, and provides patient recruitment when
clinical trials are outsourced (Mendivil, 2012). Consequently, globalization of the clinical
trials increases complexity, as well as, making it difficult to achieve global quality and
patient safety (Paul et al., 2011). In developing countries, 1,589 out of 1,940 drugs are
identified as registered, and there were 351 drugs not registered with limited information
on drug's clinical trials and known side effects (Bate, Mooney, & Hess, 2011). Because
of the complexity of the clinical trials and faster completion timelines, drugs’ side effects
are underreported and causing thousands of deaths, hospitalization due to tragedies, and
lack of drug registry (Soni & Singh, 2013)
The pharmaceutical senior leaders should address outsourced clinical trial risks
and complexities by creating sustainable quality management plans to avoid quality
system breakdowns in outsourced clinical trials. The results of this study indicated that
building vendor-client relationships, having vendor quality management and successful
implementation of QMS can help avoid quality system breaks. The ultimate goal for both
pharmaceutical organizations and outsourced clinical vendors is bringing the safest and
most effective drug for patients to have a better life.
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Appendix A: Consent Letter for Participant over 18 Years of Age
You are invited to take part in a research study titled Total Quality Systems breakdowns of
Outsourcing Clinical Trials. The research objective is to improve quality of outsourced
clinical trials in Asia Pacific developing countries. The researcher is inviting Quality
Assurance Managers who have experience in the clinical arena in the pharmaceutical industry and
have worked with outsourced vendors to be in the study. This form is part of a process called
“informed consent” to allow you to understand this study before deciding whether to take part.
This study is being conducted by a researcher named Hemali Barrios, who is a doctoral student at
Walden University. You may already know the researcher as a Quality Assurance colleague, but
this study is separate from that role.
Background Information:

The purpose of this study is to explore what strategies some clinical quality assurance
managers use to avoid a breakdown in quality with outsourced clinical trials in AsiaPacific countries. The information provided by clinical quality assurance managers may
contribute to social change through the creation of strategies to avoid quality breakdowns
with outsourced clinical trials.
Procedures:
If you agree to be in this study, you will be asked to:
 Attend thirty to forty five minute interview session either face-to-face or telephone
interview. After each interview you will be asked to review interview transcripts for
accuracy.
 If either interview session is not viable then e-mail questionnaire will be sent to you to
return to the researcher within three business days from receipt.
 A follow up 15-30 minute session may be needed if the researcher needs to clarify your
interview answers or if you would like additional sessions to further add to the interview
questions
Here are some sample questions:

1. How do clinical quality assurance manage to regulate the clinical quality
management systems, so it protects and adapt to changes when outsourced to
Asia Pacific?
2. What are some risks and benefits associated with clinical trials when outsourced
to Asia Pacific?
Voluntary Nature of the Study:
This study is voluntary. Everyone will respect your decision of whether or not you choose to be in
the study. No one at Novartis Pharmaceuticals Cooperation will treat you differently if you decide
not to be in the study. If you decide to join the study now, you can still change your mind later.
You may stop at any time.
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Risks and Benefits of Being in the Study:
Being in this type of study involves some risk of the minor discomforts that can be encountered in
daily life, such as, stress or being uncomfortable being interviewed. Being in this study would not
pose risk to your safety or wellbeing. The benefit of being in the study is providing information
that can help improving quality for outsourced clinical trials.
Payment:
There will be no payment or compensation for participating in this study.

Privacy:
Any information you provide will be kept confidential. The researcher will not use your personal
information for any purposes outside of this research project. Also, the researcher will not include
your name or anything else that could identify you in the study reports. Data will be kept secure
by encrypted, and password protected computer files and labeled by the participant's coded name
on the researcher personal computer. Data will be kept for a period of at least 5 years, as required
by the university.
Contacts and Questions:
You may ask any questions you have now. Or if you have questions later, you may contact the
researcher via 862-345-0642. If you want to talk privately about your rights as a participant, you
can call Dr. Leilani Endicott. She is the Walden University representative who can discuss this
with you. Her phone number is 612-312-1210. Walden University’s approval number for this
study is IRB approval is 09-01-15-0155581 and it expires on August 31 2016.
The researcher will give you a copy of this form to keep, if you choose a face-to-face interview.
Please print or save this consent form for your records if you choose to do an e-mail questionnaire
or telephone interview
Statement of Consent:
I have read the above information and I feel I understand the study well enough to make a
decision about my involvement. By signing below, or replying to this e-mail with the words, “I
consent”, I understand that I am agreeing to the terms described above.

Printed Name of Participant
Date of consent
Participant’s Signature
Researcher’s Signature
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Appendix B: Interview Questions
1. How do clinical quality assurance managers regulate the clinical quality
management systems and adapt to changes when trials are outsourced to Asia
Pacific?
2. How do clinical quality assurance managers ensure that clinical trial vendors
adapt to the changes in the environment and process negative feedback?
3. What actions are taken by clinical quality assurance managers to ensure
outsourced clinical trial vendors are following the agreed contracts?
4. What strategies do clinical quality assurance managers employ to ensure
compliance from an outsourced clinical trial vendor after an agreed quality
contract?
5. What are some risks and benefits associated with clinical trials when outsourced
to Asia Pacific?
6. How do clinical quality assurance managers build successful relationships with
clinical trial vendors and sustain those relationships with an ever-changing
outsourcing business model?
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7. How do clinical quality assurance managers ensure standard methods of
communication of newly released standard operating processes, regulations,
systems, and tools to outsourced clinical trial vendors?
8. In a 1-year time frame, how often do clinical quality assurance managers and
outsourcing vendors reassess quality agreements, contracts, processes, and
potential gaps?
9. What strategies have/have not worked with outsourcing clinical trials to ensure
the highest quality of the clinical trial?
10. Is there any additional information you would like add that I may not have
addressed by the interview questions?
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Appendix C: Invitation to Participate in Research Study

Dear_______________,

This is to notify you that Walden University Doctoral student Hemali Barrios is
conducting a research study titled Total Quality Systems breakdowns of Outsourced
Clinical Trials. The purpose of this qualitative case study is to explore pharmaceutical
leaders’ procedural policies to ensure that outsourcing companies use proper quality
clinical trial processes. This knowledge ensures outsourcing companies use proper
quality clinical trial processes in order to enhance data quality of the clinical trial.
Your participation will consist of a 30 minute interview session. This study is voluntary.
Everyone will respect your decision of whether or not you choose to be in the study. No
one at Novartis Pharmaceutical organization will treat you differently if you decide not to
be in the study. If you decide to join the study now, you can still change your mind later.
You may withdraw any time during the research study. Any information provided during
the study is confidential. Feel free to contact me to express your interest in participation.
Thank you for your consideration.

Sincerely,

Hemali Barrios
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Appendix D: Confidentiality Agreement

Name of Signer:

Hemali Barrios

During the course of my activity in collecting data for this research: “Total Quality
System Breakdown in Outsource Clinical Trials” I will have access to information, which
is confidential and should not be disclosed. I acknowledge that the information must
remain confidential, and that improper disclosure of confidential information can be
damaging to the participant.
By signing this Confidentiality Agreement I acknowledge and agree that:
1. I will not disclose or discuss any confidential information with others, including
friends or family.
2. I will not in any way divulge, copy, release, sell, loan, alter or destroy any
confidential information except as properly authorized.
3. I will not discuss confidential information where others can overhear the
conversation. I understand that it is not acceptable to discuss confidential information
even if the participant’s name is not used.
4. I will not make any unauthorized transmissions, inquiries, modification or purging of
confidential information.
5. I agree that my obligations under this agreement will continue after termination of
the job that I will perform.
6. I understand that violation of this agreement will have legal implications.
7. I will only access or use systems or devices I’m officially authorized to access and I
will not demonstrate the operation or function of systems or devices to unauthorized
individuals.
Signing this document, I acknowledge that I have read the agreement and I agree to
comply with all the terms and conditions stated above.

Signature:

Date:
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Appendix E: Protecting Human Research Participants

Certificate of Completion
The National Institutes of Health (NIH) Office of Extramural Research
certifies that Hemali Barrios successfully completed the NIH Webbased training course “Protecting Human Research Participants”.
Date of completion: 07/09/2013
Certification Number: 1210496
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Appendix F: Organizational Consent

NNOVARTIS

July 23, 2015

Joanne Spallone
Global Head, Clinical Quality
Assurance

Novartis Pharmaceuticals
Corporation
One Health Plaza
East Hanover, NJ 07936
Tel
Fax
E-mail
joanne.spalline@novartis.com

Dear Hemali Barrios,
Based on my review of your research proposal, I give permission for you to conduct the
study entitled Total Quality Systems breakdowns in Outsourced Clinical Trials within the
Novartis Pharmaceutical Corporation. As part of this study, I authorize you to gain access
to the purposive sample of clinical quality assurance managers from an invitation via email or through teleconference meeting invitations. In addition, authorization for any
follow-up question with a phone call or e-mail to answer any questions or concerns the
participants may have about the study via e-mail, in person, or via teleconference. A copy
of the approved IRB informed consent will be sent to me prior to obtaining access to
potential research participants. After participants gave confirmation to volunteer for the
study, I will authorize you to send an IRB approved informed consent to the clinical
quality assurance managers via e-mail or in person. According to Novartis policy there
will be no audio recorded sessions with research participants. I authorize you to collect
data by conducting semistructured interviews via e-mail, in person, or teleconference. I
understand the semistructured interview will consist of 10 construct study specific sets of
open-ended questions and after each interview the researcher will transcribe verbatim the
interview and will perform a member check with each research participant to review
transcribed interview scripts to ensure accuracy of the researcher data interpretation. I
understand that the research study will be published and any Novartis identifiers will be
de identified. Dissemination of the results will be given to each participants or
stakeholder by debriefing sessions for overall study results. Individuals’ participation will
be voluntary and at their own discretion.
We understand that our organization’s responsibilities include: giving access to research
participants (clinical quality assurance managers), and the use of Novartis conference
rooms to conduct interviews, and allow review of Novartis policies and quality reports. It
is assumed that the supervision of the research activities is by Walden’s University’s
remote faculty members. We reserve the right to withdraw from the study at any time if
our circumstances change.
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I confirm that I am authorized to approve research in this setting and that this plan
complies with the organization’s policies.
I understand that the data collected will remain entirely confidential and may not be
provided to anyone outside of the student’s supervising faculty/staff without permission
from the Walden University IRB.

Sincerely,
NOVARTIS PHARMACEUTICALS CORPORATION

Joanne Spallone
Global Head, Clinical Quality Assurance

